Primary prevention of colorectal cancer.
Journal: 2010/May - Gastroenterology
ISSN: 1528-0012
Abstract:
Colorectal cancer has been strongly associated with a Western lifestyle. In the past several decades, much has been learned about the dietary, lifestyle, and medication risk factors for this malignancy. Although there is controversy about the role of specific nutritional factors, consideration of dietary pattern as a whole appears useful for formulating recommendations. For example, several studies have shown that high intake of red and processed meats, highly refined grains and starches, and sugars is related to increased risk of colorectal cancer. Replacing these factors with poultry, fish, and plant sources as the primary source of protein; unsaturated fats as the primary source of fat; and unrefined grains, legumes and fruits as the primary source of carbohydrates is likely to lower risk of colorectal cancer. Although a role for supplements, including vitamin D, folate, and vitamin B6, remains uncertain, calcium supplementation is likely to be at least modestly beneficial. With respect to lifestyle, compelling evidence indicates that avoidance of smoking and heavy alcohol use, prevention of weight gain, and maintenance of a reasonable level of physical activity are associated with markedly lower risks of colorectal cancer. Medications such as aspirin and nonsteroidal anti-inflammatory drugs and postmenopausal hormones for women are associated with substantial reductions in colorectal cancer risk, though their utility is affected by associated risks. Taken together, modifications in diet and lifestyle should substantially reduce the risk of colorectal cancer and could complement screening in reducing colorectal cancer incidence.
Relations:
Content
Citations
(158)
References
(415)
Diseases
(1)
Drugs
(6)
Chemicals
(2)
Organisms
(2)
Processes
(1)
Affiliates
(3)
Similar articles
Articles by the same authors
Discussion board
Gastroenterology 138(6): 2029-2043e10.

Primary Prevention of Colorectal Cancer

Introduction

In the United States, colorectal cancer is the third leading cause of cancer death in each sex and second overall in men and women combined. In 2009, an estimated 146,970 men and women will be newly diagnosed with colorectal cancer; 49,920 deaths will be attributable to the disease. At current rates, approximately 5%–6% of individuals will develop a cancer of the colon or rectum within their lifetime.1 Before the 1900s, colorectal cancer was relatively uncommon in the U.S., but its incidence rose dramatically over the last century in parallel with economic development. Worldwide, the majority of colorectal cancers continue to occur in industrialized countries, although incidence rates are rapidly rising in less-developed nations as they increasingly adopt features of a Western lifestyle.2 Migration studies also demonstrate a higher lifetime incidence of colorectal cancer among immigrants to high-incidence, industrialized countries compared to residents remaining in their native, low-incidence countries. Taken together, these data highlight the importance of environmental influences on colorectal carcinogenesis. 3

In this review, we provide an overview of the epidemiological evidence supporting the roles of diet, lifestyle, and medication use in colorectal cancer risk. Moreover, we focus on those risk factors that are potentially modifiable, including overall dietary patterns, avoidance of smoking, excessive alcohol, weight gain, maintenance of a reasonable level of physical activity, and use of aspirin. The cornerstones of colorectal cancer prevention are screening and detection of adenomatous polyps. However, improving our understanding of the modifiable risk factors might inform additional primary prevention strategies that can further reduce risk.4 In addition, because many of the diet and lifestyle characteristics that are related to colorectal carcinogenesis appear to be important for other major chronic diseases, adopting the appropriate changes to these risk factors are likely to improve overall health.

DIET

Fruit, Vegetables, and Fiber

The concept that a diet that is high in fiber, especially from fruits and vegetables, lowers risk of colorectal cancer has been in existence for more than 4 decades, following the observation of the relative rarity of colorectal cancers in African populations that consume a high-fiber diet.5 Fiber has been proposed to dilute or adsorb fecal carcinogens, modulate colonic transit time, alter bile acid metabolism, reduce colonic pH, or increase the production of short-chain fatty acids.6 Subsequently, the relation between colorectal cancer and fiber, as well as fruits and vegetables more generally, has been evaluated in case-control and cohort studies. The majority of case-control studies have shown an association between higher intake of fiber, vegetables, and possibly fruits, and lower risk of colon cancer.7 A meta-analysis of 6 such case-control studies found that a high intake of vegetables or fiber was associated with an approximate 40% to 50% reduction in risk for colon cancer.8 Similarly, a pooled analysis of 13 case-control studies reported an approximately 50% lower risk of colon cancer associated with higher intake of fiber.9

However, as case-control evidence for the fiber hypothesis appeared to be consolidating, results from large prospective cohort studies emerged that showed a nonexistent or weak association between dietary fiber intake and colon cancer.41012 In data from a prospective study conducted among the female U.S. nurses enrolled in the Nurses’ Health Study (NHS), we found that a high-fiber diet, measured by a semi-quantitative validated food frequency questionnaire, did not protect against colorectal cancer or adenoma. Furthermore, no associations were observed with specific subtypes of fiber, including cereal, fruit, or vegetable fiber or subtypes of cancer by location or stage.13 We also found null results in a detailed analysis of fruit and vegetable intake and colorectal cancer risk in this cohort.14 Similarly, in a Finnish population with a wider range of fiber intakes (16.0 to 34.1 g/day between the lowest and highest quartiles), an inverse association between colorectal cancer and total fiber intake was not seen.15 Recently, a pooled analysis of 13 prospective cohorts including over 700,000 participants did show a modest, inverse association between fiber intake and colorectal cancer. However, after accounting for other dietary risk factors, this association was no longer significant, suggesting that high fiber intake might simply have been correlated with other protective lifestyle or dietary factors.16 A pooled analysis of fruit and vegetable intake also failed to detect an association with overall colorectal cancer risk.17

The reasons for the apparent inconsistencies between the encouraging results from case-control studies and the largely null findings of cohort studies are not entirely clear. However, case-control studies may be more prone to bias because dietary information was collected after the diagnosis of cancer and individuals with cancer are more likely to recall perceived unhealthy dietary behaviors. Of note, a recent prospective study of over 500,000 individuals from 10 European populations (the EPIC study) did show an approximately 40% reduced risk of colorectal cancer among individuals with the highest intake of fiber.18 Similarly, in this population, high intake of fruit and vegetables was associated with a modest reduction in colorectal cancer risk.19 The reason for the discordance between the inverse association found between fiber and colorectal cancer in the European studies and the lack of association in other cohort studies that were primarily conducted in the U.S. might be related to differences in intake of other nutrients such as folate; folate could have anti-cancer effects (see section on B vitamins). In the U.S., the high prevalence of use of folate-containing multivitamins and the folate fortification of flour and breakfast cereals, (at least since 1998 when fortification became mandatory), might attenuate any additional effects of high-fiber fruits and vegetables, the primary source of these folate in the European populations. So, whereas fruits, vegetables, and fiber might influence colorectal cancer risk, these effects, if present, are likely to be much weaker than previously believed or may only be evident among individuals with extremely low baseline levels of intake

To specifically address the role of fiber and vegetables in cancer prevention, several randomized, placebo-controlled intervention trials of fiber supplementation on risk of recurrent adenomas among individuals with a prior history of adenoma have been conducted. Diets with large amounts of fruits and vegetables,20 wheat bran fiber supplements,21 or ispaghula fiber supplements, 22 were each found to have no effect on the risk of recurrent adenoma. In fact, ispaghula husk was associated with an unexpected increased risk of adenoma. Although it has been proposed that these trials were null due to an inadequate dose of fiber, it is unlikely that larger amounts would be well tolerated. For example, in the wheat bran supplement trial, only 74% of the high-fiber group consumed more than 75% of their supplement compared to 84% of the low-fiber group. Thus, daily, long-term consumption of higher levels of fiber probably would be impractical in the general population.21 These data, when viewed in the context of most prospective epidemiologic studies, raise questions about not only the ability of fiber supplements to reduce risk of colorectal cancer but the feasibility of such an approach.

Finally, resistant starch has been hypothesized to have specific anti-cancer properties since this form of fiber is preferentially fermented into potentially beneficial short-chain fatty acids in the colon. In preclinical models, animals fed resistant starch have a lower incidence of intestinal tumors.2324 In humans, resistant starch reduces cell proliferation in the upper part of the colonic crypts, 25 and some epidemiological studies have supported an inverse association between resistant starch intake and colorectal neoplasia.26 However, a recent multi-center randomized control trial of resistant starch at a dose of 30 g/day conducted among European individuals with Lynch syndrome failed to observe a significant reduction in risk of neoplasia after 4 years of follow-up. 27 Although higher amounts of resistant starch could conceivably be required to observe a protective effect, this dose of resistant starch was already more than three times higher than typical intake. Moreover, the overall compliance rate for this level of intake was already limited (77%), again suggesting that higher dosing may not be feasible. Longer term follow-up and further studies of resistant starch among patients without Lynch syndrome are needed.

In summary, increasing intake of fruits, vegetables, or fiber is unlikely to prevent a large proportion of colorectal cancers, particularly among a U.S. population, which has a food supply already fortified with folate and other dietary factors that might protect against colorectal neoplasia. There is also little evidence that concentrated sources of one type of fiber are efficacious, though fiber-rich diets have health benefits for other gastrointestinal conditions such as diverticular disease and constipation and possibly other chronic diseases.

Red Meat, Fat, and Carbohydrates

The effects of red meat (e.g. beef, pork, or lamb) have been examined in many epidemiologic studies; most, though not all, associate an increase in colon cancer or adenoma risk with greater intake of red meat.10122844 In a prospective study of a cohort of U.S. male health professionals, the Health Professionals Follow-up Study (HPFS), we found that men who ate beef, pork, or lamb as a main dish more than 5 times a week had a 3-fold increase in risk of colon cancer, compared with men who ate these meats less than once a month.4 Additional studies have also associated processed meats with risk.404547 In the EPIC study population, the absolute risk of developing colorectal cancer within 10 years for a 50 year old participant was 1.71% for the highest category of red and processed meat intake compared with 1.28% for the lowest category of intake.40 The specific mechanisms that underlie the association between red meat and colorectal cancer are unclear. Red meat might stimulate secretion of endogenous insulin, which is a mitogen (see section on body mass index) (Figure 1). Other relevant hypotheses include red meat as a major source of total or saturated fat, heme iron, or carcinogenic heterocyclic amines. In general, neither case-control or prospective studies have supported a specific association between fat and colorectal cancer.41012 Although some early studies had indicated an association between heme iron and colorectal cancer,4851 other studies have not produced consistent results.5254 In the NHS, prospective assessments of dietary iron intake as well as several biochemical measures of iron status indicated that iron levels were not associated with colorectal adenoma.55

An external file that holds a picture, illustration, etc.
Object name is nihms233908f1.jpg
Proposed insulin-related mechanisms that relate diet, obesity, and physical activity to colorectal cancer

Abdominal obesity, physical inactivity, and some aspects of a Western diet that stimulate insulin secretion could increase risk of colorectal cancer by causing repeated bouts of hyperinsulinemia. High levels of insulin might have direct effects on susceptible cells through insulin receptors or through IGF-1 receptors by decreasing IGF binding proteins thereby increasing free levels of IGF-1. Activation of insulin and IGF-1 receptors might lead to increased cell proliferation and reduced apoptosis, which could increase the risk tumorigenesis.248

Evidence indicates that the association between red meat and colorectal cancer might be related to the cooking process. Several studies have found that risk of colon cancer is specifically increased among meat eaters who consume meat with a heavily browned surface or meat that has been prepared at high temperatures at prolonged durations.34385657 When meat undergoes prolonged frying, grilling, or broiling at high temperatures, mutagenic heterocyclic amines are formed from creatinine, and these interact with amino acids.5860 Specific analyses focused on intake of heterocyclic amines, estimated using dietary indices of meat-associated mutagens, have associated the heterocyclic amines with colorectal adenoma or cancer. 386169 In the HPFS, higher consumption of these mutagens was associated with adenoma of the distal colon, independent of total overall meat intake. 70 Similarly, heterocyclic amines, measured using urine or leukocyte assays, have been associated with adenoma in other populations. 7172 Finally, studies examining interactions between meat intake, cooking methods, and genetic polymorphisms that modulate metabolism of heterocyclic amines also provide indirect, yet compelling support for an association between these carcinogens and colorectal neoplasia.64667380 For example, in the NHS, women with genotypes associated with rapid acetylation of meat-associated carcinogens had a particularly high risk of colorectal cancer that was associated with red meat intake (multivariate hazard ratio [HR], 3.01; 95% confidence interval [CI], 1.10–8.18). In contrast, women with genotypes associated with slow acetylation did not have a significantly higher risk of cancer with increased red meat intake (multivariate HR, 0.87; 95% CI, 0.35–2.17).81 Alternative sources of animal protein, including low-fat dairy products, fish, and poultry, have been associated with reduced risk of colon cancer or adenoma, compared with that of red meat, in most, but not all studies.410122930398283 These results do not support an overall adverse effect of protein intake on cancer risk, and even suggest a reduction in risk. The mechanism that underlies this reduction is unknown, but these foods are good sources of methionine, which could improve the regulation of DNA methylation. In addition, some, but not all, studies have associated sources of animal protein, especially fish, that are high in n-3 fatty acids with reduced risk of colorectal cancer.408488 Recent data from a large prospective U.S. cohort suggested either a weak or non-existent association, with a possible differential effect according to sex. Intake of marine n-3 fatty acids was not associated with colorectal cancer risk among men, but was modestly associated with lower risk among women. However, even this benefit was attenuated after adjustment for other risk factors.89 A similar potential sex difference was also suggested in a meta-analysis of studies examining fish intake and risk of colorectal cancer.84 Multiple animals and in vitro studies have shown that n-3 fatty acids reduce inflammation, 90 disrupt activity of the nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2), competitively inhibit arachidonic acid metabolism, and induce 15-prostaglandin dehydrogenase (15-PGDH), a physiological COX-2 antagonist.879192 Each of these mechanisms could retard carcinogenesis (see section on aspirin and NSAIDs) (Figure 2). In summary, limiting intake of processed meat and red meat, especially after high-temperature cooking, and replacing these foods with poultry or fish as alternative protein sources could be a reasonable approach to reducing risk of colorectal cancer.

An external file that holds a picture, illustration, etc.
Object name is nihms233908f2.jpg
Proposed inflammatory mechanisms relating diet, lifestyle, and medication use to colorectal cancer

Dietary components (e.g. vitamin D and n-3 fatty acids), lifestyle factors (e.g. physical activity), and medications (e.g. aspirin, COX-2 inhibitors, NSAIDs), might have anticancer effects (red lines) whereas lifestyle factors such as obesity could promote cancer (black lines) through anti-inflammatory mechanisms that are largely mediated through inhibition of the COX-2 enzyme. COX-2 could be upregulated by inflammatory or oncogenic stimuli via inflammatory cytokines such as or interleukin-6 (IL-6) or others that induce nuclear factor κB (NF-κB). COX-2 converts membrane-associated arachidonic acid to prostaglandins, including PGH2, PGD2, PGF2α, PGI2 (prostacyclin), and thromboxane A2, as well as PGE2. In turn, PGE2 stimulates EP2, which upregulates transcriptional activity of β-catenin and activates the oncogene products phosphatidylinositol-3-kinase (PI3K) and the kinase AKT. PGE2 also stimulates EP4, which triggers phosphorylation of the epidermal growth factor receptor (EGFR),411 thereby activating PI3K, AKT, and the oncogenic RAS–mitogen-activated protein kinase (MAPK) cascade. PGE2 stimulation of PI3K signaling also activates the transcriptional activity of the peroxisome-proliferator–activated receptor δ (PPAR δ). These PGE2-induced signaling pathways induce expression of a number of genes, including the angiogenic factor vascular endothelial growth factor (VEGF), the anti-apoptotic factor Bcl-2, and the proliferation-promoting factor cyclin D1. Many of the downstream targets of PGE2 act in positive feedback loops to induce greater expression of COX-2 (green arrows). Aspirin and NSAIDs might also directly stimulate PPARs412413 and block phosphorylation of AKT.414 15-prostaglandin dehydrogenase (15-PGDH) inhibits PGE2 and thereby functions as a prostaglandin-degrading enzyme.415417 Upregulation of prostaglandin synthesis increases urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), the major metabolite of PGE2.418

Beyond fats and proteins, there is some evidence associating intake of highly refined carbohydrates with colorectal cancer.129394 Intake of highly refined carbohydrates stimulates short-term surges of insulin secretion, which might stimulate colonic carcinogenesis (see section on body mass index) (Figure 1). Some studies have associated diets with a high glycemic load or glycemic index with risk of colorectal adenoma or cancer.9599 However, many other studies have failed to confirm these associations.100107

Calcium and Vitamin D

Calcium has been proposed to reduce risk of colorectal cancer by binding to toxic secondary bile acids and ionized fatty acids to form insoluble soaps in the lumen of the colon, 108109 or by directly reducing proliferation, stimulating differentiation, and inducing apoptosis in the colonic mucosa.110112 Large prospective studies have consistently shown a modest and significant inverse association between calcium intake and colorectal cancer risk.113 In an analysis of cases from the NHS and HPFS, total, dietary and supplemental calcium reduced the risk of distal colon cancer but not of proximal colon cancer.114 Notably, most of the risk reduction was achieved by attaining intakes of 700 to 800 mg/day, which suggests a threshold level above which further calcium would not be beneficial. In a recent analysis that pooled the results of 10 large, prospective cohort studies, those in the highest quintile of calcium intake had a 22% reduction in risk of colorectal cancer, compared to those in the lowest quintile.115

The findings from observational studies have been confirmed in randomized, placebo-controlled trials conducted among patients with a history of adenoma. Results of an intervention trial of calcium supplementation (1200 mg of elemental calcium vs. placebo) among 913 participants found a moderate but statistically significant reduction in risk of recurrent adenoma at 4 years; the rate of new adenomas was 31% among those assigned calcium and 38% among those assigned placebo.116 In subsequent analyses, the benefit was most pronounced for advanced adenoma, with a risk ratio of 0.65 (95% CI, 0.46–0.93) compared to placebo,117 and the effect of calcium persisted for at least 5 years after cessation of treatment.118 Moreover, the protective effect of calcium appeared entirely limited to those with higher 25-hydroxy-[25-(OH)] vitamin D levels.119 Similar results were observed for 2 g elemental calcium daily versus placebo in a European trial, although the result was not statistically significant in this relatively small study.22

In 1980, Garland and Garland proposed that lower levels of vitamin D, resulting from reduced solar ultraviolet-B radiation exposure, could account for the increase in mortality from colon cancer among populations at higher latitudes.120 Vitamin D could reduce risk of colorectal cancer through various mechanisms, including reducing cell proliferation, inhibiting angiogenesis, promoting cell differentiation, and stimulating apoptosis.110111121 Increasing data also indicate an anti-inflammatory mechanism (Figure 2). In animal models of colitis, deficiency of the vitamin D receptor resulted in severe inflammation,122123 whereas vitamin D supplements inhibited colitis and COX-2 expression.124126 In humans, polymorphisms in the vitamin D receptor and vitamin D deficiency have been associated with inflammatory bowel disease,127131 gingival inflammation,132 and periodontal disease, a marker for chronic inflammation.133 Vitamin D supplements were also associated with a dose-dependent decrease in the inflammatory marker C-reactive protein (CRP) in an intervention study.134 It is not clear whether the actions of vitamin D require calcium; calcium-dependent and calcium-independent mechanisms have been proposed.110111119 Several prospective studies have examined circulating levels of 25(OH)-D and found an inverse association with rectal cancer,135 colorectal cancer, or adenoma. 119136143 In a meta-analysis of these studies, based on 535 colorectal cancer cases, individuals with serum levels of 25(OH) ≥33 ng/mL (82 nmol/L) had 50% lower incidence of colorectal cancer (p<0.01) than individuals with levels less than 12 ng/mL (30 nmol/L).144 The 2 largest studies included in the meta-analysis were from the NHS and the Women’s Health Initiative (WHI), a randomized placebo-controlled trial of 400 IU vitamin D plus 1000 mg/day of calcium in 36,282 post-menopausal women. The NHS study showed, based on 193 incident cases of colorectal cancer, that the relative risk of colorectal cancer decreased linearly across quintiles of plasma 25-(OH) vitamin D concentration, with a 47% risk reduction for the highest compared to the lowest quintile.137 Similarly, in the WHI study, an inverse association was observed between baseline levels of 25-(OH) vitamin D and colorectal cancer risk.143

However, the results of the WHI study did not support a protective role of the calcium and vitamin D intervention on colorectal cancer risk over a follow-up period of 7 years. Nonetheless, this trial had some important limitations. First, the vitamin D dose of 400 IU/day was probably inadequate to yield a substantial contrast between the group given vitamin D and the group given placebo. Specifically, the expected increase in serum levels of 25-(OH) vitamin D following an increment of 400 IU/day would be approximately 3 ng/ml. In comparison, in the epidemiologic studies of 25-(OH) vitamin D, the difference between the highest and lowest quintiles was at least 20 ng/mL. Second, for the calcium intervention, most of the women also had baseline calcium intakes of more than 1000 mg/day, exceeding the threshold for a benefit based on the observational studies. Third, 7 years of follow-up might have been insufficient to show an effect on cancer incidence. The epidemiologic data on duration, although limited, indicate that any influence of calcium and vitamin D intake on colorectal cancer risk could require at least 10 years to emerge.145 Finally, the WHI study had a factorial design and also examined a hormone replacement intervention. In a post-hoc analysis, we found that women that were randomly assigned to the group that was given hormones did not have a lower risk of colorectal cancer from vitamin D and calcium, whereas women who did not take hormones did benefit.146

In summary, data support a significant, yet modest ability of calcium intake to prevent colorectal cancer. The precise mechanism by which vitamin D prevents colorectal cancer is not clear, but future randomized control trials of higher doses of vitamin D might provide more information. Although an association between colorectal cancer and vitamin D has not been definitively proven, it is important to achieve a level of at least 30 ng/mL, since this dose has been shown to be optimal for other health conditions.

B Vitamins

B vitamins are integral components of one-carbon metabolism, which affects processes that influence cancer risk such as DNA synthesis, repair, and methylation. Based on this premise, B vitamins, particularly folate and vitamin B6, have been studied in relation to risk of colorectal cancer. Folate has received most attention. Studies that have examined folate intake in relation to risk of colorectal cancer or adenoma have largely shown that higher intakes are typically associated with reduced risk.147 Specifically, one meta-analysis found an association with dietary folate but not with folate from supplements.148 This finding suggests either that correlated factors other than, or in combination with folate are the truly protective factors, or that the form of folate administration could influence its effectiveness. Consistent with experimental data that folate deficiency may induce p53 mutations, low dietary folate has also been specifically associated with increased risk of colorectal cancers with p53 mutations but not wild-type tumors.149 Also relevant to the folate hypothesis is the role of methylenetetrahydrofolate reductase (MTHFR), an enzyme at a critical metabolic branch point that directs the folate pool towards remethylation of homocysteine to methionine at the expense of thymidylate synthesis. A functionally variant form of MTHFR has been consistently associated with risk of colorectal cancer, especially when considered in conjunction with intakes of folate or alcohol.147150 The finding with MTHFR tends to add further credence of a biologic role for folate in colorectal carcinogenesis (Figure 3).

An external file that holds a picture, illustration, etc.
Object name is nihms233908f3.jpg
Proposed mechanism relating folate, alcohol, MTHFR genotype, and colorectal cancer

(THIS FIGURE IS BEING PREPARED BY ILLUSTRATOR) The TT genotype of MTHFR is associated with impaired function of the MTHFR enzyme in converting 5,10-methylene tetrahydrofolate (THF) into 5-methyl THF. For individuals with CC or CT genotypes, only modest associations are observed between folate, alcohol, and risk of colorectal neoplasia. However, individuals with the TT genotype might be particularly sensitive to the anti-cancer effects of high folate intake and low alcohol consumption. Specifically, with high stores of folate, the higher levels of 5,10-methyl THR might prevent imbalances of nucleotide pools during DNA synthesis (e.g. reduced uracil misincorporation) and a sufficient amount of 5,10-methylene THF is converted to 5-methyl THF for DNA methylation. In contrast, when the methyl content in the diet is low or depleted by alcohol consumption, individuals with TT genotypes might be less able to compensate for the impairment in MTHFR function; therefore, these individuals are less able to produce sufficient amounts of 5-methyl THF for DNA methylation. Impairment of DNA methylation processes results in dysregulation of gene expression.419

This observational data and the supporting mechanistic evidence provided the impetus to conduct several randomized controlled trials of folic acid (the synthetic form of folate) in relation to risk of subsequent adenomas in individuals with a history of adenoma. In contrast with the observational studies, these trials tended not to support a benefit of folic acid given at 0.5 mg or 1 mg daily. 151152 In fact, one trial suggested a possible increased risk of recurrent advanced adenoma or multiple adenomas related to excessive folate.153 These studies indicate that an additional supplement of folic acid is unlikely to be beneficial, and even harmful, for those who already have had a colonic neoplasm. However, the effect of folic acid may differ among individuals with baseline folate deficiency. In our recent randomized trial, although folic acid supplementation was not associated with overall reduction in risk of recurrent adenoma, participants with low plasma folate concentrations at baseline did experience a significant decrease in adenoma recurrence (RR, 0.61; 95% CI: 0.42, 0.90).152 It is also possible that future studies may suggest a role for measuring baseline plasma folate levels prior to use of folate supplementation. The timing of supplementation may also be a key determinant of its effect on neoplasia. Studies from animal models have shown that adequate dietary folate can suppress initial tumor formation, but excess folate during later stages of carcinogenesis could promote carcinogenesis.154 Taken together with observations that methylation patterns can be altered even in the apparently normal mucosa of patients with tumors, there could be a preexisting “field defect” in the colonic mucosa of patients with prior adenoma that folic acid is unable to reverse.155 Finally, there is evidence that more than a decade would be required to observe any preventative effects of folate on colorectal carcinogenesis—this time period exceeds that of short-term randomized trials to monitor development of adenoma. In summary, most individuals should receive the recommended 400 µg/day of folate, but it is not clear whether higher doses are beneficial or harmful with respect to colorectal cancer prevention. Due to food fortification in the U.S., few in the U.S. are folate deficient; however, folate-deficient populations, particularly those without a prior history of neoplasia, could benefit from supplements to prevent colorectal cancer.

Only in the past several years has the association between vitamin B6 and risk of colorectal cancer received adequate study. Vitamin B6 is involved in many cellular functions, so it could have anti-cancer mechanisms beyond its role in one-carbon metabolism. Remarkably, most studies have associated higher intake of vitamin B6 or higher levels of pyridoxal 5'-phosphate (PLP), the main circulating form of B6, with a 30%–40% decrease in risk of colorectal cancer.156162 In many of the studies, the inverse association between vitamin B6 and colorectal cancer was even stronger than that observed for folate; the decrease in risk might be greatest among individuals with heavy intake of alcohol. Dietary B6 intake may also be preferentially associated with risk of colorectal cancers with p53 mutations.149 Of note, there is some data which suggest that vitamin B6 increases risk for rectal cancer.163 Clearly, interventional studies are required to clarify whether vitamin B6 does reduce the incidence of colorectal cancer. In summary, based on current evidence, it is not recommended that intake of vitamin B6 be increased to prevent colorectal cancer.

Antioxidants and Other Micronutrients

Several other dietary micronutrients, including selenium, beta carotene, and vitamins A, C, and E are believed to have anti-carcinogenic effects, based on their anti-oxidant or anti-inflammatory properties and findings from observational studies.8294164168 Perhaps the strongest relationships have been observed with selenium. With a few exceptions,169170 most studies have demonstrated an inverse association between colorectal adenoma and selenium levels, measured from toenail or plasma samples.171177 Moreover, a remarkable, statistically significant, 50% reduction in colorectal cancer incidence and a non-significant reduction in adenoma incidence were observed in study participants given selenium in the form of brewer’s yeast; skin cancer incidence was reduced in another study of selenium.176178 However, randomized trials specifically designed to examine antioxidant supplements have not supported these observational results. A recent randomized, placebo-controlled trial of oral selenium (200 microgram/d) and vitamin E (400 IU/d), given alone or in combination to men, did not find any reduction in risk prespecified cancer endpoints, including colorectal cancer.179 A randomized, placebo-controlled trial of vitamin E (50 mg/d), beta carotene (20 mg/day), or the combination in male smokers in Finland did not find that these micronutrients reduced colorectal cancer incidence, yet raised concerns about increased risk for lung cancer and ischemic heart disease related to beta carotene intake.180 Randomized, placebo controlled-trials of patients with prior adenoma did not demonstrate reduced risk of recurrent adenoma in patients given beta carotene supplements,181 a combination of vitamin C, vitamin E, and beta carotene supplements,182 or a diet high in anti-oxidant rich fruits and vegetables.20 A meta-analysis of randomized trials of antioxidant supplements, including beta-carotene and vitamins A, C, and E, did not find that these nutrients reduced incidence of gastrointestinal cancers.171 In summary, antioxidant vitamin supplements do not appear to prevent colorectal cancer.

Dietary Patterns

Recognizing the potential for interactive and synergistic effects between various dietary components, researchers have examined the relationship between colorectal cancer and dietary patterns, rather than specific macronutrients or micronutrients. The NHS associated a “Western diet”, consisting of large amounts of red meat and highly refined carbohydrates, with increased risk of colorectal cancer, compared to a “prudent diet” that includes only small amounts of red meat and refined carbohydrates.183 These results have been largely supported by analyses of dietary patterns in other populations.184186 Mechanistically, the potential anti-cancer benefit of such dietary patterns might be related to hyperinsulinemia (Figure 1) or inflammation (Figure 2). In summary, although the relative importance of and mechanisms associated with specific macronutrient components or micronutrients are uncertain, consideration of the overall dietary pattern might be more important in modifying colorectal cancer risk.

Fruit, Vegetables, and Fiber

The concept that a diet that is high in fiber, especially from fruits and vegetables, lowers risk of colorectal cancer has been in existence for more than 4 decades, following the observation of the relative rarity of colorectal cancers in African populations that consume a high-fiber diet.5 Fiber has been proposed to dilute or adsorb fecal carcinogens, modulate colonic transit time, alter bile acid metabolism, reduce colonic pH, or increase the production of short-chain fatty acids.6 Subsequently, the relation between colorectal cancer and fiber, as well as fruits and vegetables more generally, has been evaluated in case-control and cohort studies. The majority of case-control studies have shown an association between higher intake of fiber, vegetables, and possibly fruits, and lower risk of colon cancer.7 A meta-analysis of 6 such case-control studies found that a high intake of vegetables or fiber was associated with an approximate 40% to 50% reduction in risk for colon cancer.8 Similarly, a pooled analysis of 13 case-control studies reported an approximately 50% lower risk of colon cancer associated with higher intake of fiber.9

However, as case-control evidence for the fiber hypothesis appeared to be consolidating, results from large prospective cohort studies emerged that showed a nonexistent or weak association between dietary fiber intake and colon cancer.41012 In data from a prospective study conducted among the female U.S. nurses enrolled in the Nurses’ Health Study (NHS), we found that a high-fiber diet, measured by a semi-quantitative validated food frequency questionnaire, did not protect against colorectal cancer or adenoma. Furthermore, no associations were observed with specific subtypes of fiber, including cereal, fruit, or vegetable fiber or subtypes of cancer by location or stage.13 We also found null results in a detailed analysis of fruit and vegetable intake and colorectal cancer risk in this cohort.14 Similarly, in a Finnish population with a wider range of fiber intakes (16.0 to 34.1 g/day between the lowest and highest quartiles), an inverse association between colorectal cancer and total fiber intake was not seen.15 Recently, a pooled analysis of 13 prospective cohorts including over 700,000 participants did show a modest, inverse association between fiber intake and colorectal cancer. However, after accounting for other dietary risk factors, this association was no longer significant, suggesting that high fiber intake might simply have been correlated with other protective lifestyle or dietary factors.16 A pooled analysis of fruit and vegetable intake also failed to detect an association with overall colorectal cancer risk.17

The reasons for the apparent inconsistencies between the encouraging results from case-control studies and the largely null findings of cohort studies are not entirely clear. However, case-control studies may be more prone to bias because dietary information was collected after the diagnosis of cancer and individuals with cancer are more likely to recall perceived unhealthy dietary behaviors. Of note, a recent prospective study of over 500,000 individuals from 10 European populations (the EPIC study) did show an approximately 40% reduced risk of colorectal cancer among individuals with the highest intake of fiber.18 Similarly, in this population, high intake of fruit and vegetables was associated with a modest reduction in colorectal cancer risk.19 The reason for the discordance between the inverse association found between fiber and colorectal cancer in the European studies and the lack of association in other cohort studies that were primarily conducted in the U.S. might be related to differences in intake of other nutrients such as folate; folate could have anti-cancer effects (see section on B vitamins). In the U.S., the high prevalence of use of folate-containing multivitamins and the folate fortification of flour and breakfast cereals, (at least since 1998 when fortification became mandatory), might attenuate any additional effects of high-fiber fruits and vegetables, the primary source of these folate in the European populations. So, whereas fruits, vegetables, and fiber might influence colorectal cancer risk, these effects, if present, are likely to be much weaker than previously believed or may only be evident among individuals with extremely low baseline levels of intake

To specifically address the role of fiber and vegetables in cancer prevention, several randomized, placebo-controlled intervention trials of fiber supplementation on risk of recurrent adenomas among individuals with a prior history of adenoma have been conducted. Diets with large amounts of fruits and vegetables,20 wheat bran fiber supplements,21 or ispaghula fiber supplements, 22 were each found to have no effect on the risk of recurrent adenoma. In fact, ispaghula husk was associated with an unexpected increased risk of adenoma. Although it has been proposed that these trials were null due to an inadequate dose of fiber, it is unlikely that larger amounts would be well tolerated. For example, in the wheat bran supplement trial, only 74% of the high-fiber group consumed more than 75% of their supplement compared to 84% of the low-fiber group. Thus, daily, long-term consumption of higher levels of fiber probably would be impractical in the general population.21 These data, when viewed in the context of most prospective epidemiologic studies, raise questions about not only the ability of fiber supplements to reduce risk of colorectal cancer but the feasibility of such an approach.

Finally, resistant starch has been hypothesized to have specific anti-cancer properties since this form of fiber is preferentially fermented into potentially beneficial short-chain fatty acids in the colon. In preclinical models, animals fed resistant starch have a lower incidence of intestinal tumors.2324 In humans, resistant starch reduces cell proliferation in the upper part of the colonic crypts, 25 and some epidemiological studies have supported an inverse association between resistant starch intake and colorectal neoplasia.26 However, a recent multi-center randomized control trial of resistant starch at a dose of 30 g/day conducted among European individuals with Lynch syndrome failed to observe a significant reduction in risk of neoplasia after 4 years of follow-up. 27 Although higher amounts of resistant starch could conceivably be required to observe a protective effect, this dose of resistant starch was already more than three times higher than typical intake. Moreover, the overall compliance rate for this level of intake was already limited (77%), again suggesting that higher dosing may not be feasible. Longer term follow-up and further studies of resistant starch among patients without Lynch syndrome are needed.

In summary, increasing intake of fruits, vegetables, or fiber is unlikely to prevent a large proportion of colorectal cancers, particularly among a U.S. population, which has a food supply already fortified with folate and other dietary factors that might protect against colorectal neoplasia. There is also little evidence that concentrated sources of one type of fiber are efficacious, though fiber-rich diets have health benefits for other gastrointestinal conditions such as diverticular disease and constipation and possibly other chronic diseases.

Red Meat, Fat, and Carbohydrates

The effects of red meat (e.g. beef, pork, or lamb) have been examined in many epidemiologic studies; most, though not all, associate an increase in colon cancer or adenoma risk with greater intake of red meat.10122844 In a prospective study of a cohort of U.S. male health professionals, the Health Professionals Follow-up Study (HPFS), we found that men who ate beef, pork, or lamb as a main dish more than 5 times a week had a 3-fold increase in risk of colon cancer, compared with men who ate these meats less than once a month.4 Additional studies have also associated processed meats with risk.404547 In the EPIC study population, the absolute risk of developing colorectal cancer within 10 years for a 50 year old participant was 1.71% for the highest category of red and processed meat intake compared with 1.28% for the lowest category of intake.40 The specific mechanisms that underlie the association between red meat and colorectal cancer are unclear. Red meat might stimulate secretion of endogenous insulin, which is a mitogen (see section on body mass index) (Figure 1). Other relevant hypotheses include red meat as a major source of total or saturated fat, heme iron, or carcinogenic heterocyclic amines. In general, neither case-control or prospective studies have supported a specific association between fat and colorectal cancer.41012 Although some early studies had indicated an association between heme iron and colorectal cancer,4851 other studies have not produced consistent results.5254 In the NHS, prospective assessments of dietary iron intake as well as several biochemical measures of iron status indicated that iron levels were not associated with colorectal adenoma.55

An external file that holds a picture, illustration, etc.
Object name is nihms233908f1.jpg
Proposed insulin-related mechanisms that relate diet, obesity, and physical activity to colorectal cancer

Abdominal obesity, physical inactivity, and some aspects of a Western diet that stimulate insulin secretion could increase risk of colorectal cancer by causing repeated bouts of hyperinsulinemia. High levels of insulin might have direct effects on susceptible cells through insulin receptors or through IGF-1 receptors by decreasing IGF binding proteins thereby increasing free levels of IGF-1. Activation of insulin and IGF-1 receptors might lead to increased cell proliferation and reduced apoptosis, which could increase the risk tumorigenesis.248

Evidence indicates that the association between red meat and colorectal cancer might be related to the cooking process. Several studies have found that risk of colon cancer is specifically increased among meat eaters who consume meat with a heavily browned surface or meat that has been prepared at high temperatures at prolonged durations.34385657 When meat undergoes prolonged frying, grilling, or broiling at high temperatures, mutagenic heterocyclic amines are formed from creatinine, and these interact with amino acids.5860 Specific analyses focused on intake of heterocyclic amines, estimated using dietary indices of meat-associated mutagens, have associated the heterocyclic amines with colorectal adenoma or cancer. 386169 In the HPFS, higher consumption of these mutagens was associated with adenoma of the distal colon, independent of total overall meat intake. 70 Similarly, heterocyclic amines, measured using urine or leukocyte assays, have been associated with adenoma in other populations. 7172 Finally, studies examining interactions between meat intake, cooking methods, and genetic polymorphisms that modulate metabolism of heterocyclic amines also provide indirect, yet compelling support for an association between these carcinogens and colorectal neoplasia.64667380 For example, in the NHS, women with genotypes associated with rapid acetylation of meat-associated carcinogens had a particularly high risk of colorectal cancer that was associated with red meat intake (multivariate hazard ratio [HR], 3.01; 95% confidence interval [CI], 1.10–8.18). In contrast, women with genotypes associated with slow acetylation did not have a significantly higher risk of cancer with increased red meat intake (multivariate HR, 0.87; 95% CI, 0.35–2.17).81 Alternative sources of animal protein, including low-fat dairy products, fish, and poultry, have been associated with reduced risk of colon cancer or adenoma, compared with that of red meat, in most, but not all studies.410122930398283 These results do not support an overall adverse effect of protein intake on cancer risk, and even suggest a reduction in risk. The mechanism that underlies this reduction is unknown, but these foods are good sources of methionine, which could improve the regulation of DNA methylation. In addition, some, but not all, studies have associated sources of animal protein, especially fish, that are high in n-3 fatty acids with reduced risk of colorectal cancer.408488 Recent data from a large prospective U.S. cohort suggested either a weak or non-existent association, with a possible differential effect according to sex. Intake of marine n-3 fatty acids was not associated with colorectal cancer risk among men, but was modestly associated with lower risk among women. However, even this benefit was attenuated after adjustment for other risk factors.89 A similar potential sex difference was also suggested in a meta-analysis of studies examining fish intake and risk of colorectal cancer.84 Multiple animals and in vitro studies have shown that n-3 fatty acids reduce inflammation, 90 disrupt activity of the nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2), competitively inhibit arachidonic acid metabolism, and induce 15-prostaglandin dehydrogenase (15-PGDH), a physiological COX-2 antagonist.879192 Each of these mechanisms could retard carcinogenesis (see section on aspirin and NSAIDs) (Figure 2). In summary, limiting intake of processed meat and red meat, especially after high-temperature cooking, and replacing these foods with poultry or fish as alternative protein sources could be a reasonable approach to reducing risk of colorectal cancer.

An external file that holds a picture, illustration, etc.
Object name is nihms233908f2.jpg
Proposed inflammatory mechanisms relating diet, lifestyle, and medication use to colorectal cancer

Dietary components (e.g. vitamin D and n-3 fatty acids), lifestyle factors (e.g. physical activity), and medications (e.g. aspirin, COX-2 inhibitors, NSAIDs), might have anticancer effects (red lines) whereas lifestyle factors such as obesity could promote cancer (black lines) through anti-inflammatory mechanisms that are largely mediated through inhibition of the COX-2 enzyme. COX-2 could be upregulated by inflammatory or oncogenic stimuli via inflammatory cytokines such as or interleukin-6 (IL-6) or others that induce nuclear factor κB (NF-κB). COX-2 converts membrane-associated arachidonic acid to prostaglandins, including PGH2, PGD2, PGF2α, PGI2 (prostacyclin), and thromboxane A2, as well as PGE2. In turn, PGE2 stimulates EP2, which upregulates transcriptional activity of β-catenin and activates the oncogene products phosphatidylinositol-3-kinase (PI3K) and the kinase AKT. PGE2 also stimulates EP4, which triggers phosphorylation of the epidermal growth factor receptor (EGFR),411 thereby activating PI3K, AKT, and the oncogenic RAS–mitogen-activated protein kinase (MAPK) cascade. PGE2 stimulation of PI3K signaling also activates the transcriptional activity of the peroxisome-proliferator–activated receptor δ (PPAR δ). These PGE2-induced signaling pathways induce expression of a number of genes, including the angiogenic factor vascular endothelial growth factor (VEGF), the anti-apoptotic factor Bcl-2, and the proliferation-promoting factor cyclin D1. Many of the downstream targets of PGE2 act in positive feedback loops to induce greater expression of COX-2 (green arrows). Aspirin and NSAIDs might also directly stimulate PPARs412413 and block phosphorylation of AKT.414 15-prostaglandin dehydrogenase (15-PGDH) inhibits PGE2 and thereby functions as a prostaglandin-degrading enzyme.415417 Upregulation of prostaglandin synthesis increases urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), the major metabolite of PGE2.418

Beyond fats and proteins, there is some evidence associating intake of highly refined carbohydrates with colorectal cancer.129394 Intake of highly refined carbohydrates stimulates short-term surges of insulin secretion, which might stimulate colonic carcinogenesis (see section on body mass index) (Figure 1). Some studies have associated diets with a high glycemic load or glycemic index with risk of colorectal adenoma or cancer.9599 However, many other studies have failed to confirm these associations.100107

Calcium and Vitamin D

Calcium has been proposed to reduce risk of colorectal cancer by binding to toxic secondary bile acids and ionized fatty acids to form insoluble soaps in the lumen of the colon, 108109 or by directly reducing proliferation, stimulating differentiation, and inducing apoptosis in the colonic mucosa.110112 Large prospective studies have consistently shown a modest and significant inverse association between calcium intake and colorectal cancer risk.113 In an analysis of cases from the NHS and HPFS, total, dietary and supplemental calcium reduced the risk of distal colon cancer but not of proximal colon cancer.114 Notably, most of the risk reduction was achieved by attaining intakes of 700 to 800 mg/day, which suggests a threshold level above which further calcium would not be beneficial. In a recent analysis that pooled the results of 10 large, prospective cohort studies, those in the highest quintile of calcium intake had a 22% reduction in risk of colorectal cancer, compared to those in the lowest quintile.115

The findings from observational studies have been confirmed in randomized, placebo-controlled trials conducted among patients with a history of adenoma. Results of an intervention trial of calcium supplementation (1200 mg of elemental calcium vs. placebo) among 913 participants found a moderate but statistically significant reduction in risk of recurrent adenoma at 4 years; the rate of new adenomas was 31% among those assigned calcium and 38% among those assigned placebo.116 In subsequent analyses, the benefit was most pronounced for advanced adenoma, with a risk ratio of 0.65 (95% CI, 0.46–0.93) compared to placebo,117 and the effect of calcium persisted for at least 5 years after cessation of treatment.118 Moreover, the protective effect of calcium appeared entirely limited to those with higher 25-hydroxy-[25-(OH)] vitamin D levels.119 Similar results were observed for 2 g elemental calcium daily versus placebo in a European trial, although the result was not statistically significant in this relatively small study.22

In 1980, Garland and Garland proposed that lower levels of vitamin D, resulting from reduced solar ultraviolet-B radiation exposure, could account for the increase in mortality from colon cancer among populations at higher latitudes.120 Vitamin D could reduce risk of colorectal cancer through various mechanisms, including reducing cell proliferation, inhibiting angiogenesis, promoting cell differentiation, and stimulating apoptosis.110111121 Increasing data also indicate an anti-inflammatory mechanism (Figure 2). In animal models of colitis, deficiency of the vitamin D receptor resulted in severe inflammation,122123 whereas vitamin D supplements inhibited colitis and COX-2 expression.124126 In humans, polymorphisms in the vitamin D receptor and vitamin D deficiency have been associated with inflammatory bowel disease,127131 gingival inflammation,132 and periodontal disease, a marker for chronic inflammation.133 Vitamin D supplements were also associated with a dose-dependent decrease in the inflammatory marker C-reactive protein (CRP) in an intervention study.134 It is not clear whether the actions of vitamin D require calcium; calcium-dependent and calcium-independent mechanisms have been proposed.110111119 Several prospective studies have examined circulating levels of 25(OH)-D and found an inverse association with rectal cancer,135 colorectal cancer, or adenoma. 119136143 In a meta-analysis of these studies, based on 535 colorectal cancer cases, individuals with serum levels of 25(OH) ≥33 ng/mL (82 nmol/L) had 50% lower incidence of colorectal cancer (p<0.01) than individuals with levels less than 12 ng/mL (30 nmol/L).144 The 2 largest studies included in the meta-analysis were from the NHS and the Women’s Health Initiative (WHI), a randomized placebo-controlled trial of 400 IU vitamin D plus 1000 mg/day of calcium in 36,282 post-menopausal women. The NHS study showed, based on 193 incident cases of colorectal cancer, that the relative risk of colorectal cancer decreased linearly across quintiles of plasma 25-(OH) vitamin D concentration, with a 47% risk reduction for the highest compared to the lowest quintile.137 Similarly, in the WHI study, an inverse association was observed between baseline levels of 25-(OH) vitamin D and colorectal cancer risk.143

However, the results of the WHI study did not support a protective role of the calcium and vitamin D intervention on colorectal cancer risk over a follow-up period of 7 years. Nonetheless, this trial had some important limitations. First, the vitamin D dose of 400 IU/day was probably inadequate to yield a substantial contrast between the group given vitamin D and the group given placebo. Specifically, the expected increase in serum levels of 25-(OH) vitamin D following an increment of 400 IU/day would be approximately 3 ng/ml. In comparison, in the epidemiologic studies of 25-(OH) vitamin D, the difference between the highest and lowest quintiles was at least 20 ng/mL. Second, for the calcium intervention, most of the women also had baseline calcium intakes of more than 1000 mg/day, exceeding the threshold for a benefit based on the observational studies. Third, 7 years of follow-up might have been insufficient to show an effect on cancer incidence. The epidemiologic data on duration, although limited, indicate that any influence of calcium and vitamin D intake on colorectal cancer risk could require at least 10 years to emerge.145 Finally, the WHI study had a factorial design and also examined a hormone replacement intervention. In a post-hoc analysis, we found that women that were randomly assigned to the group that was given hormones did not have a lower risk of colorectal cancer from vitamin D and calcium, whereas women who did not take hormones did benefit.146

In summary, data support a significant, yet modest ability of calcium intake to prevent colorectal cancer. The precise mechanism by which vitamin D prevents colorectal cancer is not clear, but future randomized control trials of higher doses of vitamin D might provide more information. Although an association between colorectal cancer and vitamin D has not been definitively proven, it is important to achieve a level of at least 30 ng/mL, since this dose has been shown to be optimal for other health conditions.

B Vitamins

B vitamins are integral components of one-carbon metabolism, which affects processes that influence cancer risk such as DNA synthesis, repair, and methylation. Based on this premise, B vitamins, particularly folate and vitamin B6, have been studied in relation to risk of colorectal cancer. Folate has received most attention. Studies that have examined folate intake in relation to risk of colorectal cancer or adenoma have largely shown that higher intakes are typically associated with reduced risk.147 Specifically, one meta-analysis found an association with dietary folate but not with folate from supplements.148 This finding suggests either that correlated factors other than, or in combination with folate are the truly protective factors, or that the form of folate administration could influence its effectiveness. Consistent with experimental data that folate deficiency may induce p53 mutations, low dietary folate has also been specifically associated with increased risk of colorectal cancers with p53 mutations but not wild-type tumors.149 Also relevant to the folate hypothesis is the role of methylenetetrahydrofolate reductase (MTHFR), an enzyme at a critical metabolic branch point that directs the folate pool towards remethylation of homocysteine to methionine at the expense of thymidylate synthesis. A functionally variant form of MTHFR has been consistently associated with risk of colorectal cancer, especially when considered in conjunction with intakes of folate or alcohol.147150 The finding with MTHFR tends to add further credence of a biologic role for folate in colorectal carcinogenesis (Figure 3).

An external file that holds a picture, illustration, etc.
Object name is nihms233908f3.jpg
Proposed mechanism relating folate, alcohol, MTHFR genotype, and colorectal cancer

(THIS FIGURE IS BEING PREPARED BY ILLUSTRATOR) The TT genotype of MTHFR is associated with impaired function of the MTHFR enzyme in converting 5,10-methylene tetrahydrofolate (THF) into 5-methyl THF. For individuals with CC or CT genotypes, only modest associations are observed between folate, alcohol, and risk of colorectal neoplasia. However, individuals with the TT genotype might be particularly sensitive to the anti-cancer effects of high folate intake and low alcohol consumption. Specifically, with high stores of folate, the higher levels of 5,10-methyl THR might prevent imbalances of nucleotide pools during DNA synthesis (e.g. reduced uracil misincorporation) and a sufficient amount of 5,10-methylene THF is converted to 5-methyl THF for DNA methylation. In contrast, when the methyl content in the diet is low or depleted by alcohol consumption, individuals with TT genotypes might be less able to compensate for the impairment in MTHFR function; therefore, these individuals are less able to produce sufficient amounts of 5-methyl THF for DNA methylation. Impairment of DNA methylation processes results in dysregulation of gene expression.419

This observational data and the supporting mechanistic evidence provided the impetus to conduct several randomized controlled trials of folic acid (the synthetic form of folate) in relation to risk of subsequent adenomas in individuals with a history of adenoma. In contrast with the observational studies, these trials tended not to support a benefit of folic acid given at 0.5 mg or 1 mg daily. 151152 In fact, one trial suggested a possible increased risk of recurrent advanced adenoma or multiple adenomas related to excessive folate.153 These studies indicate that an additional supplement of folic acid is unlikely to be beneficial, and even harmful, for those who already have had a colonic neoplasm. However, the effect of folic acid may differ among individuals with baseline folate deficiency. In our recent randomized trial, although folic acid supplementation was not associated with overall reduction in risk of recurrent adenoma, participants with low plasma folate concentrations at baseline did experience a significant decrease in adenoma recurrence (RR, 0.61; 95% CI: 0.42, 0.90).152 It is also possible that future studies may suggest a role for measuring baseline plasma folate levels prior to use of folate supplementation. The timing of supplementation may also be a key determinant of its effect on neoplasia. Studies from animal models have shown that adequate dietary folate can suppress initial tumor formation, but excess folate during later stages of carcinogenesis could promote carcinogenesis.154 Taken together with observations that methylation patterns can be altered even in the apparently normal mucosa of patients with tumors, there could be a preexisting “field defect” in the colonic mucosa of patients with prior adenoma that folic acid is unable to reverse.155 Finally, there is evidence that more than a decade would be required to observe any preventative effects of folate on colorectal carcinogenesis—this time period exceeds that of short-term randomized trials to monitor development of adenoma. In summary, most individuals should receive the recommended 400 µg/day of folate, but it is not clear whether higher doses are beneficial or harmful with respect to colorectal cancer prevention. Due to food fortification in the U.S., few in the U.S. are folate deficient; however, folate-deficient populations, particularly those without a prior history of neoplasia, could benefit from supplements to prevent colorectal cancer.

Only in the past several years has the association between vitamin B6 and risk of colorectal cancer received adequate study. Vitamin B6 is involved in many cellular functions, so it could have anti-cancer mechanisms beyond its role in one-carbon metabolism. Remarkably, most studies have associated higher intake of vitamin B6 or higher levels of pyridoxal 5'-phosphate (PLP), the main circulating form of B6, with a 30%–40% decrease in risk of colorectal cancer.156162 In many of the studies, the inverse association between vitamin B6 and colorectal cancer was even stronger than that observed for folate; the decrease in risk might be greatest among individuals with heavy intake of alcohol. Dietary B6 intake may also be preferentially associated with risk of colorectal cancers with p53 mutations.149 Of note, there is some data which suggest that vitamin B6 increases risk for rectal cancer.163 Clearly, interventional studies are required to clarify whether vitamin B6 does reduce the incidence of colorectal cancer. In summary, based on current evidence, it is not recommended that intake of vitamin B6 be increased to prevent colorectal cancer.

Antioxidants and Other Micronutrients

Several other dietary micronutrients, including selenium, beta carotene, and vitamins A, C, and E are believed to have anti-carcinogenic effects, based on their anti-oxidant or anti-inflammatory properties and findings from observational studies.8294164168 Perhaps the strongest relationships have been observed with selenium. With a few exceptions,169170 most studies have demonstrated an inverse association between colorectal adenoma and selenium levels, measured from toenail or plasma samples.171177 Moreover, a remarkable, statistically significant, 50% reduction in colorectal cancer incidence and a non-significant reduction in adenoma incidence were observed in study participants given selenium in the form of brewer’s yeast; skin cancer incidence was reduced in another study of selenium.176178 However, randomized trials specifically designed to examine antioxidant supplements have not supported these observational results. A recent randomized, placebo-controlled trial of oral selenium (200 microgram/d) and vitamin E (400 IU/d), given alone or in combination to men, did not find any reduction in risk prespecified cancer endpoints, including colorectal cancer.179 A randomized, placebo-controlled trial of vitamin E (50 mg/d), beta carotene (20 mg/day), or the combination in male smokers in Finland did not find that these micronutrients reduced colorectal cancer incidence, yet raised concerns about increased risk for lung cancer and ischemic heart disease related to beta carotene intake.180 Randomized, placebo controlled-trials of patients with prior adenoma did not demonstrate reduced risk of recurrent adenoma in patients given beta carotene supplements,181 a combination of vitamin C, vitamin E, and beta carotene supplements,182 or a diet high in anti-oxidant rich fruits and vegetables.20 A meta-analysis of randomized trials of antioxidant supplements, including beta-carotene and vitamins A, C, and E, did not find that these nutrients reduced incidence of gastrointestinal cancers.171 In summary, antioxidant vitamin supplements do not appear to prevent colorectal cancer.

Dietary Patterns

Recognizing the potential for interactive and synergistic effects between various dietary components, researchers have examined the relationship between colorectal cancer and dietary patterns, rather than specific macronutrients or micronutrients. The NHS associated a “Western diet”, consisting of large amounts of red meat and highly refined carbohydrates, with increased risk of colorectal cancer, compared to a “prudent diet” that includes only small amounts of red meat and refined carbohydrates.183 These results have been largely supported by analyses of dietary patterns in other populations.184186 Mechanistically, the potential anti-cancer benefit of such dietary patterns might be related to hyperinsulinemia (Figure 1) or inflammation (Figure 2). In summary, although the relative importance of and mechanisms associated with specific macronutrient components or micronutrients are uncertain, consideration of the overall dietary pattern might be more important in modifying colorectal cancer risk.

LIFESTYLE

Alcohol

The relationship between alcohol and cancer has been controversial, but most evidence indicates that high intake of alcohol increases risk of colorectal cancer.187 The association between alcohol intake and colon adenoma and cancer risk has been observed in most,165166188208 but not all, prospective cohort and case-control studies.209212 The HPFS indicated that men who drink more than 2 drinks of alcohol per day had a 2-fold higher risk of colon cancer compared to men who drank less than 0.25 drinks per day.213 In NHS and HPFS, we have also demonstrated an increased risk of colorectal adenoma with heavy alcohol use. 214 A pooled analysis of 8 prospective cohort studies (including the NHS and HPFS), which included nearly 500,000 participants, yielded a multivariate risk of colorectal cancer of 1.24 (95% CI 1.07–1.42) for consumption of ≥30 g/day of alcohol compared to low intake.215 Similar associations were observed in the EPIC cohort that also included nearly 500,000 participants.216 This association is not confounded by other risk factors for colorectal cancer and is generally observed for both rectal and colon cancers, as well as for specific types of beverage (beer vs. wine). A meta-analysis corroborated these findings.217 Of note, a recent study did suggest that alcohol was particularly associated with rectal cancers compared with colon cancers as well as with microsatellite instability low (MSI-L) compared with microsatellite instability high (MSI-H) tumors.218 Because most studies have associated colorectal cancer risk with the highest levels of intake, it is not clear whether intake of less than 30 g/day (about 2 drinks/day) alcohol affects risk. The mechanisms by which alcohol promote cancer are unknown, but the ability of alcohol to reduce folate levels is of interest (see section on folate) (Figure 3).219 In addition, alcohol might antagonize metabolism of methyl groups, contributing to abnormal DNA methylation.220 Finally, alcohol could suppress tumor immune surveillance, delay DNA repair, alter composition of bile acids, or induce cytochrome p450 enzymes to activate hepatic carcinogens. 221 In summary, it appears prudent to recommend minimizing alcohol intake as a means of preventing colorectal cancer, especially among individuals with high levels of intake.

Tobacco

The classic studies that linked smoking to cancer incidence and mortality did not associate cigarette smoking with an increased risk of colorectal cancer;222225 most likely because of the long time lag between exposure and colorectal tumor formation, which is approximately 30 to 40 years.226227 Tobacco releases a range of carcinogenic compounds, including polynuclear aromatic hydrocarbons, heterocyclic amines, nitrosamines, and aromatic amines,228 that can reach the colorectal mucosa through the circulatory system or direct ingestion.229 Tobacco use has been consistently associated with an increased risk of colorectal adenoma; the time required for this association is shorter than for colorectal cancer.230

Many of the findings on tobacco and colorectal neoplasia risk were summarized in 1 recent meta-analysis of adenoma studies,231 and 3 meta-analyses of cancer studies, which generally reached similar conclusions.232234 One of the meta-analyses examined 4 dose-response variables, each of which yielded statistically significant results: daily cigarette consumption (38% risk increase for an increment of 40 cigarettes/day), duration (20% risk increase for an increment of 40 years of duration), pack-years (51% risk increase for an increment of 60 pack-years), and age of initiation (4% decrease in risk for a delay of 10 years in smoking initiation).233 Interestingly, the incidence of colorectal cancer also appeared to be stronger in past smokers than in current smokers, consistent with the initiation of an irreversible early event, such as genetic damage. However, a more recent prospective study suggests that past smokers who quit for at least 31 years no longer had an increased risk.235 The association appeared to be stronger for rectal cancer than for colon cancer, and possibly for the proximal colon compared to the distal colon,232236 as well as for MSI-H compared with MSI-L tumors.218 Studies of population-attributable risks in the U.S. have estimated that approximately 15%–20% of colorectal cancers can be attributed to smoking; the proportion might be higher for rectal than for colon cancers.227237239 In summary, because cessation of smoking late in life does not necessarily eliminate the increased risk for colorectal cancer, it is critical to prevent smoking in adolescents and young adults and to convince smokers to quit as early in life as possible. Although not presently recommended, more intensive screening of smokers for colorectal neoplasia may be justified given the approximately 2-fold increase in risk of being diagnosed with an adenoma and a higher risk of colorectal cancer mortality associated with current smoking.240

Body Mass and Fat Distribution

Case-control and prospective studies have consistently associated excess body weight (or body mass index [BMI]; kg/m2) with an increased risk of colon cancer.12168241244 The HPFS showed that BMI is directly associated with risk, with men in the highest quintile of BMI having nearly a 2-fold higher risk of colon cancer compared with men in the lowest quintile.242 In NHS, women with a BMI >29 kg/m had a 1.5-fold increased risk of colon cancer243 and 2-fold increased risk of large (≥ 1cm) adenoma.245 We recently completed a meta-analysis of 56 case-control and cohort studies, conducted among 7,213,335 individuals including 93 812 cases of colorectal cancer.246 In that analysis, compared with those with a BMI < 23.0 kg/m, the increased risk of colorectal cancer were 14% for individuals with a BMI of 23.0–24.9; 19% for a BMI of 25.0–27.4; 24% for BMI of 27.5–29.9; and 41% for BMI of ≥30.0 kg/m. The association was stronger for men than for women, and for the colon than for the rectum. For rectal cancer, a weak association was observed only for men but not for women. In a separate meta-analysis of prospective studies, colon cancer risk increased with increasing waist circumference (33% increased risk in men and 16% increase in women per 10-cm increment in waist circumference). Increasing waist-hip-ratio (WHR) was also associated with an increased risk in both men and women.247 Controls for various other lifestyle factors did not appreciably alter the findings for BMI or body circumference measures.

The mechanisms whereby obesity increases risk for colon cancer are not well established. However, the mitogenic properties of insulin, obesity-related insulin resistance, and associated hyperinsulinemia might be involved in colon cancer pathogenesis (Figure 1).248 Insulin could also promote colorectal carcinogenesis by increasing levels of bioactive insulin-like growth factor (IGF)-1, either directly or through decreasing levels of IGF binding proteins levels, which leads to increased free IGF-1. In the Physicians’ Health Study (PHS) of male physicians,249 there was 2.5-fold increased risk of colorectal cancer with increasing levels of plasma C-peptide (a marker of insulin secretion) when extreme quintiles (highest vs. lowest) were compared. With a few notable exceptions,250 most other studies have supported this association.251255 The largest prospective study, which included 1078 cases of colorectal cancer, found that increased levels of C-peptide were associated with a 37% increase in colorectal cancer risk among men and women.251 Levels of adiponectin, an insulin-sensitizing adipokine, have been inversely associated with the risk of colorectal cancer; men in the HPFS in the highest quintile of adiponectin had a relative risk (RR) of 0.40 (95% CI, 0.22–0.74) for colorectal cancer compared with men in the lowest quintile.256 Another study has also associated adiponectin with adenoma.257

Individuals with diabetes mellitus have also been shown to have an increased risk of colorectal cancer.258262 This may be related not only the previously reviewed metabolic consequences of obesity, physical inactivity, and insulin resistance, but also hyperglycemia associated with the disease. However, the evidence supporting a link between hyperglycemia and colorectal cancer data is inconsistent. Glycosylated hemoglobin (HbA1c), a widely used measure of blood glucose control in patients with diabetes, has been shown to be a more stable indictor of glycemia over a prior 6 to 8 week period than direct measures of plasma glucose. In a large, prospective case-control study nested in the EPIC cohort, increasing HbA1c was associated with a modestly increased risk of colorectal cancer in women, but not men.263 HbAic was also associated with risk of colorectal cancer in three other small studies.47254264 However, several other studies have suggested no association of HbA1c with risk of colorectal cancer or adenoma.265267

Based on these findings, obesity, particularly central adiposity, appears to affect risk of colorectal cancer. As shown in Figure 1, factors that increase insulin resistance, such as abdominal obesity and a sedentary lifestyle, combined with dietary factors (see section on red meat and carbohydrates) that stimulate insulin secretion, might induce hyperinsulinemia, which increases risk for colorectal cancer., Obesitymay also be a pro-inflammatory state, whichhas also beenlinked to cancer. (Figure 2). 268271 For example, a recent study demonstrated an increase in expression of the pro-inflammatory enzyme cyclooxygenase-2 (COX-2) in normal mucosa adjacent to colorectal tumors patients that were overweight, compared to patients with a healthy body mass index (BMI)272 In addition, in a placebo-controlled trial, patients with higher BMIs that were given an aspirin daily (325-mg) had a greater reduction in risk of recurrent adenoma (RR=0.44) than those with normal weight (RR=1.23) (see section on aspirin and NSAIDs).273

Physical Activity

An association between greater levels of physical activity and decreased risk of colon cancer has been one of the most consistently observed.274275 The inverse association for colon cancer has been observed both in prospective cohort and case-control studies. In the HPFS, we showed that physical activity was inversely associated with risk for colon cancer, with a RR of 0.53 (95% CI, 0.32–0.88) for men in the highest quintile of activity, compared to men in the lowest quintile.242 Similarly, in the NHS, women who expended >21 metabolic equivalent task-hours (MET-hours)/week had a RR of colon cancer of 0.54 (CI, 0.33–0.90), compared with women who expended< 2 MET-hours/week.245 Moreover, higher levels of physical activity have been associated with a reduced risk of colon adenoma and particularly large or advanced lesions.242245276277 Although a physically active lifestyle might be associated with other healthful behaviors, a number of characteristics of the findings indicate that higher levels of physical activity level directly prevent lower colon cancer. The association has been consistently reported in many studies of various designs, in diverse populations, for men and women, and after statistical control for a variety of other lifestyle factors.242278280 A compelling finding is that the inverse association has been observed for both leisure-time and occupational activities, for which patterns of potential confounding lifestyle characteristics are likely to differ.

Overall, the results from these studies indicate a dose-response relation, with risk reduction present across a wide range of physical activity frequency and intensity. In a recent meta-analysis of 52 studies, physically active individuals had a 20%–30% lower risk of colon cancer compared to less active individuals.281 Whereas risk might be further reduced with even higher levels of activity, even moderate levels of physical activity (e.g., brisk walking for 3–4 hours/week) are associated with substantial benefits. The mechanisms by which physical activity reduces cancer risk is not known, but could involve, in part, reductions in insulin levels (Figure 1),282283 and systemic inflammation (Figure 2). Physical activity could also increase colonic motility, though colonic motility has not been definitely linked to colon cancer risk. The cancer-preventing effects of physical activity might also be partially mediated by reducing abdominal adiposity. Nonetheless, evidence supports maintaining a high level of physical activity, even in the absence of significant weight loss, to lower risk of colorectal cancer. In summary, routine physical activity in addition to maintenance of a healthy body weight is associated with significantly lower risk of colorectal cancer.

Alcohol

The relationship between alcohol and cancer has been controversial, but most evidence indicates that high intake of alcohol increases risk of colorectal cancer.187 The association between alcohol intake and colon adenoma and cancer risk has been observed in most,165166188208 but not all, prospective cohort and case-control studies.209212 The HPFS indicated that men who drink more than 2 drinks of alcohol per day had a 2-fold higher risk of colon cancer compared to men who drank less than 0.25 drinks per day.213 In NHS and HPFS, we have also demonstrated an increased risk of colorectal adenoma with heavy alcohol use. 214 A pooled analysis of 8 prospective cohort studies (including the NHS and HPFS), which included nearly 500,000 participants, yielded a multivariate risk of colorectal cancer of 1.24 (95% CI 1.07–1.42) for consumption of ≥30 g/day of alcohol compared to low intake.215 Similar associations were observed in the EPIC cohort that also included nearly 500,000 participants.216 This association is not confounded by other risk factors for colorectal cancer and is generally observed for both rectal and colon cancers, as well as for specific types of beverage (beer vs. wine). A meta-analysis corroborated these findings.217 Of note, a recent study did suggest that alcohol was particularly associated with rectal cancers compared with colon cancers as well as with microsatellite instability low (MSI-L) compared with microsatellite instability high (MSI-H) tumors.218 Because most studies have associated colorectal cancer risk with the highest levels of intake, it is not clear whether intake of less than 30 g/day (about 2 drinks/day) alcohol affects risk. The mechanisms by which alcohol promote cancer are unknown, but the ability of alcohol to reduce folate levels is of interest (see section on folate) (Figure 3).219 In addition, alcohol might antagonize metabolism of methyl groups, contributing to abnormal DNA methylation.220 Finally, alcohol could suppress tumor immune surveillance, delay DNA repair, alter composition of bile acids, or induce cytochrome p450 enzymes to activate hepatic carcinogens. 221 In summary, it appears prudent to recommend minimizing alcohol intake as a means of preventing colorectal cancer, especially among individuals with high levels of intake.

Tobacco

The classic studies that linked smoking to cancer incidence and mortality did not associate cigarette smoking with an increased risk of colorectal cancer;222225 most likely because of the long time lag between exposure and colorectal tumor formation, which is approximately 30 to 40 years.226227 Tobacco releases a range of carcinogenic compounds, including polynuclear aromatic hydrocarbons, heterocyclic amines, nitrosamines, and aromatic amines,228 that can reach the colorectal mucosa through the circulatory system or direct ingestion.229 Tobacco use has been consistently associated with an increased risk of colorectal adenoma; the time required for this association is shorter than for colorectal cancer.230

Many of the findings on tobacco and colorectal neoplasia risk were summarized in 1 recent meta-analysis of adenoma studies,231 and 3 meta-analyses of cancer studies, which generally reached similar conclusions.232234 One of the meta-analyses examined 4 dose-response variables, each of which yielded statistically significant results: daily cigarette consumption (38% risk increase for an increment of 40 cigarettes/day), duration (20% risk increase for an increment of 40 years of duration), pack-years (51% risk increase for an increment of 60 pack-years), and age of initiation (4% decrease in risk for a delay of 10 years in smoking initiation).233 Interestingly, the incidence of colorectal cancer also appeared to be stronger in past smokers than in current smokers, consistent with the initiation of an irreversible early event, such as genetic damage. However, a more recent prospective study suggests that past smokers who quit for at least 31 years no longer had an increased risk.235 The association appeared to be stronger for rectal cancer than for colon cancer, and possibly for the proximal colon compared to the distal colon,232236 as well as for MSI-H compared with MSI-L tumors.218 Studies of population-attributable risks in the U.S. have estimated that approximately 15%–20% of colorectal cancers can be attributed to smoking; the proportion might be higher for rectal than for colon cancers.227237239 In summary, because cessation of smoking late in life does not necessarily eliminate the increased risk for colorectal cancer, it is critical to prevent smoking in adolescents and young adults and to convince smokers to quit as early in life as possible. Although not presently recommended, more intensive screening of smokers for colorectal neoplasia may be justified given the approximately 2-fold increase in risk of being diagnosed with an adenoma and a higher risk of colorectal cancer mortality associated with current smoking.240

Body Mass and Fat Distribution

Case-control and prospective studies have consistently associated excess body weight (or body mass index [BMI]; kg/m2) with an increased risk of colon cancer.12168241244 The HPFS showed that BMI is directly associated with risk, with men in the highest quintile of BMI having nearly a 2-fold higher risk of colon cancer compared with men in the lowest quintile.242 In NHS, women with a BMI >29 kg/m had a 1.5-fold increased risk of colon cancer243 and 2-fold increased risk of large (≥ 1cm) adenoma.245 We recently completed a meta-analysis of 56 case-control and cohort studies, conducted among 7,213,335 individuals including 93 812 cases of colorectal cancer.246 In that analysis, compared with those with a BMI < 23.0 kg/m, the increased risk of colorectal cancer were 14% for individuals with a BMI of 23.0–24.9; 19% for a BMI of 25.0–27.4; 24% for BMI of 27.5–29.9; and 41% for BMI of ≥30.0 kg/m. The association was stronger for men than for women, and for the colon than for the rectum. For rectal cancer, a weak association was observed only for men but not for women. In a separate meta-analysis of prospective studies, colon cancer risk increased with increasing waist circumference (33% increased risk in men and 16% increase in women per 10-cm increment in waist circumference). Increasing waist-hip-ratio (WHR) was also associated with an increased risk in both men and women.247 Controls for various other lifestyle factors did not appreciably alter the findings for BMI or body circumference measures.

The mechanisms whereby obesity increases risk for colon cancer are not well established. However, the mitogenic properties of insulin, obesity-related insulin resistance, and associated hyperinsulinemia might be involved in colon cancer pathogenesis (Figure 1).248 Insulin could also promote colorectal carcinogenesis by increasing levels of bioactive insulin-like growth factor (IGF)-1, either directly or through decreasing levels of IGF binding proteins levels, which leads to increased free IGF-1. In the Physicians’ Health Study (PHS) of male physicians,249 there was 2.5-fold increased risk of colorectal cancer with increasing levels of plasma C-peptide (a marker of insulin secretion) when extreme quintiles (highest vs. lowest) were compared. With a few notable exceptions,250 most other studies have supported this association.251255 The largest prospective study, which included 1078 cases of colorectal cancer, found that increased levels of C-peptide were associated with a 37% increase in colorectal cancer risk among men and women.251 Levels of adiponectin, an insulin-sensitizing adipokine, have been inversely associated with the risk of colorectal cancer; men in the HPFS in the highest quintile of adiponectin had a relative risk (RR) of 0.40 (95% CI, 0.22–0.74) for colorectal cancer compared with men in the lowest quintile.256 Another study has also associated adiponectin with adenoma.257

Individuals with diabetes mellitus have also been shown to have an increased risk of colorectal cancer.258262 This may be related not only the previously reviewed metabolic consequences of obesity, physical inactivity, and insulin resistance, but also hyperglycemia associated with the disease. However, the evidence supporting a link between hyperglycemia and colorectal cancer data is inconsistent. Glycosylated hemoglobin (HbA1c), a widely used measure of blood glucose control in patients with diabetes, has been shown to be a more stable indictor of glycemia over a prior 6 to 8 week period than direct measures of plasma glucose. In a large, prospective case-control study nested in the EPIC cohort, increasing HbA1c was associated with a modestly increased risk of colorectal cancer in women, but not men.263 HbAic was also associated with risk of colorectal cancer in three other small studies.47254264 However, several other studies have suggested no association of HbA1c with risk of colorectal cancer or adenoma.265267

Based on these findings, obesity, particularly central adiposity, appears to affect risk of colorectal cancer. As shown in Figure 1, factors that increase insulin resistance, such as abdominal obesity and a sedentary lifestyle, combined with dietary factors (see section on red meat and carbohydrates) that stimulate insulin secretion, might induce hyperinsulinemia, which increases risk for colorectal cancer., Obesitymay also be a pro-inflammatory state, whichhas also beenlinked to cancer. (Figure 2). 268271 For example, a recent study demonstrated an increase in expression of the pro-inflammatory enzyme cyclooxygenase-2 (COX-2) in normal mucosa adjacent to colorectal tumors patients that were overweight, compared to patients with a healthy body mass index (BMI)272 In addition, in a placebo-controlled trial, patients with higher BMIs that were given an aspirin daily (325-mg) had a greater reduction in risk of recurrent adenoma (RR=0.44) than those with normal weight (RR=1.23) (see section on aspirin and NSAIDs).273

Physical Activity

An association between greater levels of physical activity and decreased risk of colon cancer has been one of the most consistently observed.274275 The inverse association for colon cancer has been observed both in prospective cohort and case-control studies. In the HPFS, we showed that physical activity was inversely associated with risk for colon cancer, with a RR of 0.53 (95% CI, 0.32–0.88) for men in the highest quintile of activity, compared to men in the lowest quintile.242 Similarly, in the NHS, women who expended >21 metabolic equivalent task-hours (MET-hours)/week had a RR of colon cancer of 0.54 (CI, 0.33–0.90), compared with women who expended< 2 MET-hours/week.245 Moreover, higher levels of physical activity have been associated with a reduced risk of colon adenoma and particularly large or advanced lesions.242245276277 Although a physically active lifestyle might be associated with other healthful behaviors, a number of characteristics of the findings indicate that higher levels of physical activity level directly prevent lower colon cancer. The association has been consistently reported in many studies of various designs, in diverse populations, for men and women, and after statistical control for a variety of other lifestyle factors.242278280 A compelling finding is that the inverse association has been observed for both leisure-time and occupational activities, for which patterns of potential confounding lifestyle characteristics are likely to differ.

Overall, the results from these studies indicate a dose-response relation, with risk reduction present across a wide range of physical activity frequency and intensity. In a recent meta-analysis of 52 studies, physically active individuals had a 20%–30% lower risk of colon cancer compared to less active individuals.281 Whereas risk might be further reduced with even higher levels of activity, even moderate levels of physical activity (e.g., brisk walking for 3–4 hours/week) are associated with substantial benefits. The mechanisms by which physical activity reduces cancer risk is not known, but could involve, in part, reductions in insulin levels (Figure 1),282283 and systemic inflammation (Figure 2). Physical activity could also increase colonic motility, though colonic motility has not been definitely linked to colon cancer risk. The cancer-preventing effects of physical activity might also be partially mediated by reducing abdominal adiposity. Nonetheless, evidence supports maintaining a high level of physical activity, even in the absence of significant weight loss, to lower risk of colorectal cancer. In summary, routine physical activity in addition to maintenance of a healthy body weight is associated with significantly lower risk of colorectal cancer.

MEDICATIONS

Aspirin, NSAIDs, and COX-2 Selective Inhibitors

Beginning in the 1980s and 1990s, several case-control studies, followed by prospective cohort studies, consistently associated aspirin use with a lower risk of colorectal cancer and adenoma.284299 Clinical observations and case series studies, later corroborated by the results of randomized control trials, also demonstrated that NSAIDs such as sulindac and the COX-2 selective inhibitor celecoxib reduced the adenomatous polyp burden among patients with familial adenomatous polyposis.300307 Subsequently, 4 randomized, placebo-controlled trials of aspirin provided compelling evidence that aspirin directly inhibits sporadic carcinogenesis; each trial demonstrated that short-term aspirin use reduces the risk of adenoma recurrence in patients with a prior history of colorectal neoplasia.151308310 A recent meta-analysis of these trials found that aspirin users had pooled risk ratio of 0.83 (95% CI, 0.72–0.96) for any adenoma and 0.72 (95% CI, 0.57–0.90) for advanced adenomas.311 Although 2 large trials, the PHS and the Women’s Health Study, failed to confirm that aspirin protects against colorectal cancer,312313 these findings could reflect the low doses of aspirin used or insufficient duration of treatment or follow-up. In support of this explanation, the NHS and HPFS,314315 as well as a secondary analysis of data from 2 other randomized trials, found that long-term use of higher doses of aspirin protect against colorectal cancer.316 A dose-dependent relationship is also apparent based on findings from a separate analyses of NHS participants which showed that higher doses of aspirin, especially among women with UGT1A6 polymorphisms that impair aspirin metabolism, were inversely associated with adenoma formation.317318 This finding was also observed in other cohorts.319

Three recent randomized trials showed that the COX-2 selective inhibitors celecoxib and rofecoxib prevented adenoma recurrence among patients with a prior history of adenoma.320322 In the Adenoma Prevention with Celecoxib (APC) trial, adenoma recurrence was reduced by 33%–45% in patients that received 3 years of treatment with celecoxib.322 Unfortunately, the APC trial identified a dose-dependent, 3-fold higher risk of cardiovascular events, which was also observed in a study of rofecoxib.323326 This subsequently led to the withdrawal of rofecoxib from the market. However, a recent pooled analysis of 6 randomized control trials of celecoxib in patients with non-arthritis indications found that celecoxib (400 mg twice each day) was not associated with increased cardiovascular risk among patients with low baseline risk of cardiovascular disease.327 Moreover, in the APC trial, a planned 5-year efficacy analysis found that a previous history of atherosclerotic heart disease was the only risk factor that significantly interacted with celecoxib use in the association with cardiovascular events.328 Taken together, this data indicate that celecoxib is relatively safe for individuals that are at low risk for cardiovascular disorders. Unfortunately, many risk factors for colorectal cancer (e.g. body mass index, physical inactivity) overlap with those of cardiovascular disease.329

Although there have been many observational studies supporting a role for non-aspirin, non-COX-2 selective, NSAIDs in colorectal cancer prevention,271284287289291296299330346 randomized trial data are limited. The NSAID sulindac has been shown to reduce polyp burden in patients with FAP.301303 For sporadic adenoma, data are limited to a trial of patients with a history of adenoma that examined the effects of a combination of sulindac and the ornithine decarboxylase inhibitor difluoromethylornitine (DFMO), compared with those of placebo. This combination was selected because of the ability of these reagents to synergistically reduce levels of colonic polyamines (e.g., putrescine, spermidine, and spermine), which are believed to be pro-carcinogenic. DFMO inhibits polyamine synthesis,347 whereas sulindac is believed to increase polyamine acetylation and export. In this small trial, the combination of DFMO and sulindac reduced the risk of recurrent adenoma by 70%. Although there were concerns about potential adverse effects of DFMO on hearing, there was no significant difference reported in hearing changes or audiogram results from patients given DFMO compared to those given placebo.348 However, as observed in patients given COX-2–selective NSAIDs, there appeared to be a higher incidence of cardiovascular toxicity among patients with a high baseline risk of cardiovascular events that were given sulindac.349 Because the trial was not designed to examine sulindac and DFMO separately, it is uncertain if either agent used alone is an effective chemopreventive.

There have been many proposed mechanisms by which aspirin, NSAIDs, and COX-2 selective inhibitors reduce risk of colorectal neoplasia (Figure 2). However, perhaps the most compelling hypothesis is related to the ability of these agents to inhibit COX-2. A specific role for COX-2 in colorectal neoplasia is supported by several lines of evidence: 1) disruption of COX-2 inhibits development of polyps in mice with a mutation in APC;350 2) host expression of COX-2, but not COX-1, is required for survival of mouse tumor xenografts;351 3) COX-2, but not COX-1, is progressively overexpressed in human colorectal adenomas and cancers;352353 4) COX-2 expression is highly upregulated, even in morphologically normal mucosa of APC mice and humans with colorectal cancer.354 We recently showed in a large cohort of men and women that regular aspirin use reduced the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2.355 These data indicate that aspirin likely affects the formation of adenomas and cancer by inhibiting COX-2. Similarly, a secondary analysis of data from a randomized, placebo-controlled trial of aspirin found that genetic variations in COX-2 can modify the effect of aspirin treatment on risk of recurrent adenoma.356 Nonetheless, aspirin and NSAIDs have other potential anti-cancer mechanisms that are unrelated to cyclooxygenase, including inhibition of nuclear factor-κB,357 induction of apoptosis by activation of p38 kinase,358 and catabolism of polyamines, as previously discussed.359

The preceding body of evidence was considered by the United States Preventive Services Task Force (USPSTF) in reaching a consensus statement regarding aspirin and NSAIDs for the prevention of colorectal cancer. The USPSTF concluded that overall, harms outweighed the benefits of aspirin and NSAID use for the prevention of colorectal cancer in asymptomatic adults who are at average risk for colorectal cancer.360 For COX-2-selective agents and NSAIDs, concerns about potential cardiovascular events are particularly limiting, as well as the risk of gastrointestinal ulceration and bleeding.361 Although aspirin appears to have a more favorable cardiovascular profile,362364 hemorrhagic stroke and gastrointestinal bleeding remain a concern, especially with long-term use.315 The USPSTF did advocate further investigation into optimizing the risk-benefit profile of aspirin for the purpose of cancer prevention.365 A recent international consensus panel reached a similar conclusion, advocating that additional research be conducted into the use of aspirin in high-risk populations for which benefits might outweigh the harms.366

Such a subgroup would likely include individuals with established colorectal cancer that have undergone a resection for curative intent. Although such patients generally enjoy a favorable prognosis compared to patients diagnosed with unresectable disease, they remain at high risk of recurrence and death from the disease. Thus, we recently examined, among 1,279 patients with established Stage I, II, III colorectal cancers enrolled in the NHS and HPFS, whether aspirin use can influence prognosis. We found that use of aspirin after diagnosis of colorectal cancer is associated with improved survival from the disease. Compared with non-users, participants who regularly used aspirin after diagnosis had a 29% reduction in colorectal-cancer specific mortality and a 21% reduction of overall mortality. Regular aspirin use after diagnosis was associated with a particularly low risk of colorectal-cancer specific mortality among participants in whom primary tumors overexpressed COX-2. Therefore, aspirin might influence the biology of established colorectal tumors, in addition to preventing their occurrence. Moreover, COX-2 or related markers might be used to determine which patients with newly diagnosed colorectal cancer are most likely to respond to anti-COX-2 directed therapies.367 A study performed in women with colorectal cancer also supports an effect of NSAIDs on survival.368 Nonetheless, randomized trials are needed to confirm these results before routine clinical recommendations can be implemented.

In summary, aspirin and COX-2 selective inhibitors reduce the risk of colorectal neoplasia. Presently, their routine use is not recommended for prevention of colorectal cancer in the general population due to concern about their associated toxicities. However, there are specific populations in which the potential benefit associated with their use may outweigh the risks.

Post-Menopausal Hormones

Differences in sex hormones might account for the fact that the ratio of women to men with colorectal cancer is lower before age 50–54 years (i.e. for premenopausal women) than after (i.e. for postmenopausal women).369370 This observation stimulated research into whether postmenopausal hormones reduce risk of colorectal cancer. Estrogens have been proposed to alter bile acid composition, modulate colonic transit,371 and decrease production of mitogenic insulin-like growth factor-1.372 Colorectal epithelium expresses estrogen receptors, which might be modulated by age-related promoter hypermethylation.373 Colon cancers also express estrogen receptor-β, which might modulate the effect of exogenous estrogens on tumor growth. With a few exceptions,374376 most prospective studies show an inverse association between use of postmenopausal hormones and risk of colorectal cancer. 239377393 Similarly, most studies have also shown an inverse association between postmenopausal hormone use and risk of colorectal adenoma.394398 Based on data from the NHS, postmenopausal hormone use was associated with a decreased risk of colorectal cancer (multivariate RR, 0.65; 95% CI, 0.50–0.83) and large colorectal adenoma (≥ 1cm in diameter) (multivariate RR, 0.74, 95% CI, 0.55–0.99).399 These results were confirmed in a 2 separate meta-analyses of epidemiological studies.400401

These observational results were subsequently confirmed in the WHI estrogen plus progestin randomized, placebo-controlled trial conducted among nearly 17,000 post-menopausal women. In that trial, after a mean of 5.2 years of follow-up, estrogen and progestin were associated with a 37% reduction in colorectal cancer risk, comparable with the results from prospective, observational studies. However, these results were tempered by a finding that colorectal cancers in women who were given estrogen plus progestin were diagnosed at a more advanced stage than those of patients that received placebo.402 In contrast, the WHI estrogen-alone trial did not show any benefit for colorectal cancer.403 This is in agreement with most observational studies that have also shown an inverse association between colorectal cancer and the combination of estrogen plus progestin, but not for estrogen-alone.388404405 Of note, one recent study did observe that long duration estrogen-alone therapy but not estrogen plus progestin is associated with lower risk of colorectal cancer.406

In summary, although postmenopausal hormone therapy appears to be associated with a lower risk of colorectal cancer, it remains unclear which preparations of estrogen-alone or estrogen plus progestin are optimal. Moreover, because postmenopausal hormones increase the risk of breast cancer and cardiovascular events,402 the associated balance of risks and benefits do not support a recommendation of use of postmenopausal hormones as a means of preventing colorectal cancer.407

The Overall Potential of Primary Prevention

Based on the dietary, lifestyle, and medication risk factors we have outlined, there is substantial potential for primary prevention of colorectal cancer through modification of several environmental influences. For dietary factors, although controversy exists regarding the role of specific nutritional elements, consideration of the dietary pattern as a whole might be useful for formulating recommendations. For example, several studies have shown that high intake of red and processed meats, high-fat dairy products, highly refined grains and starches, and sugars are related to a higher risk of colon cancer. Thus, replacing these factors with poultry, fish and plant sources as the primary source of protein; mono-unsaturated, and poly-unsaturated fats as the primary source of fat; and unrefined grains, legumes and fruits as the primary source of carbohydrates is likely to lower risk of colorectal cancer. This benefit is likely to be sustained irrespective of whether the independent benefit of each component or their precise anti-cancer mechanisms is established. Although the role for many supplements, including vitamin D, folate, and B6, remains largely uncertain, calcium supplementation is likely at least modestly beneficial, particularly in those with low intake of dietary calcium. Vitamin D intakes of 1000–2000 IU/day might improve overall health status and possibly lower risk of colorectal cancer.

For lifestyle factors, there is compelling evidence that avoidance of smoking and heavy alcohol use, prevention of weight gain, and the maintenance of a reasonable level of physical activity can each have a positive influence on risk of colorectal cancer. In addition, there is strong evidence that medications such as aspirin and NSAIDs are effective chemopreventive drugs. Certain preparations of postmenopausal hormones might also be associated with lower risk of colorectal cancer. Although none of these agents are recommended for widespread primary prevention due to their side effect profile, they provide proof-of-principle of the potential to translate epidemiological findings into clinically efficacious chemopreventive drug interventions.

Taken together, modification of multiple diet and lifestyle factors is likely to have a substantial overall impact on risk of colorectal cancer. In a previous study of the HPFS, as many as 70% of the overall burden of colon cancers in the U.S. population could be prevented through moderate changes in diet and lifestyle.408 Using population-based projections, a separate study reached similar conclusions, albeit with more modest estimates of benefit.409 To further integrate the combined effect of modifiable risk factors, we recently developed a comprehensive model of colon cancer incidence that accounted for changes in the influence of risk factors throughout the lifespan. We found that women with profiles of modifiable lifestyle factors that were “high risk” had a nearly 4-fold higher risk of colon cancer compared with women with “low-risk” profiles (Figure 4).410 Although endoscopic screening could reduce cancer incidence among these high-risk women, their risk remained significantly higher than women whose lifestyle behaviors placed them in the moderate- or low-risk categories (Figure 5). Thus, primary prevention of colorectal cancer through lifestyle changes is an important complement to colorectal cancer screening in reducing colon cancer incidence. Moreover, because many diet and lifestyle risk factors for colorectal cancer overlap with other chronic illnesses, including cardiovascular disease, further research into these risk factors would have benefits beyond prevention of colorectal cancer.

An external file that holds a picture, illustration, etc.
Object name is nihms233908f4.jpg
Age-specific incidence of colon cancer per 100,000 person-years according to modifiable risk factors

Women were enrolled in the Nurses’ Health Study and were followed between 1980 and 2004. Women were assumed to have no postmenopausal hormone use, no aspirin use, average height, no family history of colorectal cancer, and have never been screened for colorectal cancer. 1) a "high-risk" participant (one who accrued 10 pack-years of smoking before age 30 years, had a consistently high relative body weight, had physical activity of 2 metabolic equivalent (MET)-hours/week, consumed 1 serving of red or processed meat per day, and had a folate intake of 150 µg/day); 2) a "moderate-risk" participant (one who was a nonsmoker, had an average body mass index, had physical activity of 13.5 MET-hours/week, did not consume red or processed meat, and had a folate intake of 300 µg/day); and 3) a "low-risk" participant (one who was a nonsmoker, had a consistently low relative body weight, had physical activity of 21 MET-hours/week, did not consume red or processed meat, and had a folate intake of 400 µg/day). Taken from Wei et al.410

An external file that holds a picture, illustration, etc.
Object name is nihms233908f5.jpg
Age-specific incidence of colon cancer per 100,000 person-years according to modifiable risk factors and screening behavior

Women were enrolled in the Nurses’ Health Study and were followed between 1980 and 2004. Women were assumed to have no postmenopausal hormone use, no aspirin use, average height, no family history of colorectal cancer, and have never been screened for colorectal cancer. 1) a high-risk" participant (one who accrued 10 pack-years of smoking before age 30 years, had a consistently high relative body weight, had physical activity of 2 metabolicMET)-hours/week, consumed 1 serving of red or processed meat per day, was never screened for colon cancer, and had a folate intake of 150 µg/day); 2) a high-risk participant who was screened from age 50 years to age 70 years; 3) a "moderate-risk" participant (one who was a nonsmoker, had an average body mass index, had physical activity of 13.5 MET-hours/week, did not consume red or processed meat, was never screened, and had a folate intake of 300 µg/day); and 4) a “low-risk” participant (one who was a nonsmoker, had a consistently low relative body weight, had physical activity of 21 MET-hours/week, did not consume red or processed meat, was never screened, and had a folate intake of 400 µg/day). Taken from Wei et al.410

Aspirin, NSAIDs, and COX-2 Selective Inhibitors

Beginning in the 1980s and 1990s, several case-control studies, followed by prospective cohort studies, consistently associated aspirin use with a lower risk of colorectal cancer and adenoma.284299 Clinical observations and case series studies, later corroborated by the results of randomized control trials, also demonstrated that NSAIDs such as sulindac and the COX-2 selective inhibitor celecoxib reduced the adenomatous polyp burden among patients with familial adenomatous polyposis.300307 Subsequently, 4 randomized, placebo-controlled trials of aspirin provided compelling evidence that aspirin directly inhibits sporadic carcinogenesis; each trial demonstrated that short-term aspirin use reduces the risk of adenoma recurrence in patients with a prior history of colorectal neoplasia.151308310 A recent meta-analysis of these trials found that aspirin users had pooled risk ratio of 0.83 (95% CI, 0.72–0.96) for any adenoma and 0.72 (95% CI, 0.57–0.90) for advanced adenomas.311 Although 2 large trials, the PHS and the Women’s Health Study, failed to confirm that aspirin protects against colorectal cancer,312313 these findings could reflect the low doses of aspirin used or insufficient duration of treatment or follow-up. In support of this explanation, the NHS and HPFS,314315 as well as a secondary analysis of data from 2 other randomized trials, found that long-term use of higher doses of aspirin protect against colorectal cancer.316 A dose-dependent relationship is also apparent based on findings from a separate analyses of NHS participants which showed that higher doses of aspirin, especially among women with UGT1A6 polymorphisms that impair aspirin metabolism, were inversely associated with adenoma formation.317318 This finding was also observed in other cohorts.319

Three recent randomized trials showed that the COX-2 selective inhibitors celecoxib and rofecoxib prevented adenoma recurrence among patients with a prior history of adenoma.320322 In the Adenoma Prevention with Celecoxib (APC) trial, adenoma recurrence was reduced by 33%–45% in patients that received 3 years of treatment with celecoxib.322 Unfortunately, the APC trial identified a dose-dependent, 3-fold higher risk of cardiovascular events, which was also observed in a study of rofecoxib.323326 This subsequently led to the withdrawal of rofecoxib from the market. However, a recent pooled analysis of 6 randomized control trials of celecoxib in patients with non-arthritis indications found that celecoxib (400 mg twice each day) was not associated with increased cardiovascular risk among patients with low baseline risk of cardiovascular disease.327 Moreover, in the APC trial, a planned 5-year efficacy analysis found that a previous history of atherosclerotic heart disease was the only risk factor that significantly interacted with celecoxib use in the association with cardiovascular events.328 Taken together, this data indicate that celecoxib is relatively safe for individuals that are at low risk for cardiovascular disorders. Unfortunately, many risk factors for colorectal cancer (e.g. body mass index, physical inactivity) overlap with those of cardiovascular disease.329

Although there have been many observational studies supporting a role for non-aspirin, non-COX-2 selective, NSAIDs in colorectal cancer prevention,271284287289291296299330346 randomized trial data are limited. The NSAID sulindac has been shown to reduce polyp burden in patients with FAP.301303 For sporadic adenoma, data are limited to a trial of patients with a history of adenoma that examined the effects of a combination of sulindac and the ornithine decarboxylase inhibitor difluoromethylornitine (DFMO), compared with those of placebo. This combination was selected because of the ability of these reagents to synergistically reduce levels of colonic polyamines (e.g., putrescine, spermidine, and spermine), which are believed to be pro-carcinogenic. DFMO inhibits polyamine synthesis,347 whereas sulindac is believed to increase polyamine acetylation and export. In this small trial, the combination of DFMO and sulindac reduced the risk of recurrent adenoma by 70%. Although there were concerns about potential adverse effects of DFMO on hearing, there was no significant difference reported in hearing changes or audiogram results from patients given DFMO compared to those given placebo.348 However, as observed in patients given COX-2–selective NSAIDs, there appeared to be a higher incidence of cardiovascular toxicity among patients with a high baseline risk of cardiovascular events that were given sulindac.349 Because the trial was not designed to examine sulindac and DFMO separately, it is uncertain if either agent used alone is an effective chemopreventive.

There have been many proposed mechanisms by which aspirin, NSAIDs, and COX-2 selective inhibitors reduce risk of colorectal neoplasia (Figure 2). However, perhaps the most compelling hypothesis is related to the ability of these agents to inhibit COX-2. A specific role for COX-2 in colorectal neoplasia is supported by several lines of evidence: 1) disruption of COX-2 inhibits development of polyps in mice with a mutation in APC;350 2) host expression of COX-2, but not COX-1, is required for survival of mouse tumor xenografts;351 3) COX-2, but not COX-1, is progressively overexpressed in human colorectal adenomas and cancers;352353 4) COX-2 expression is highly upregulated, even in morphologically normal mucosa of APC mice and humans with colorectal cancer.354 We recently showed in a large cohort of men and women that regular aspirin use reduced the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2.355 These data indicate that aspirin likely affects the formation of adenomas and cancer by inhibiting COX-2. Similarly, a secondary analysis of data from a randomized, placebo-controlled trial of aspirin found that genetic variations in COX-2 can modify the effect of aspirin treatment on risk of recurrent adenoma.356 Nonetheless, aspirin and NSAIDs have other potential anti-cancer mechanisms that are unrelated to cyclooxygenase, including inhibition of nuclear factor-κB,357 induction of apoptosis by activation of p38 kinase,358 and catabolism of polyamines, as previously discussed.359

The preceding body of evidence was considered by the United States Preventive Services Task Force (USPSTF) in reaching a consensus statement regarding aspirin and NSAIDs for the prevention of colorectal cancer. The USPSTF concluded that overall, harms outweighed the benefits of aspirin and NSAID use for the prevention of colorectal cancer in asymptomatic adults who are at average risk for colorectal cancer.360 For COX-2-selective agents and NSAIDs, concerns about potential cardiovascular events are particularly limiting, as well as the risk of gastrointestinal ulceration and bleeding.361 Although aspirin appears to have a more favorable cardiovascular profile,362364 hemorrhagic stroke and gastrointestinal bleeding remain a concern, especially with long-term use.315 The USPSTF did advocate further investigation into optimizing the risk-benefit profile of aspirin for the purpose of cancer prevention.365 A recent international consensus panel reached a similar conclusion, advocating that additional research be conducted into the use of aspirin in high-risk populations for which benefits might outweigh the harms.366

Such a subgroup would likely include individuals with established colorectal cancer that have undergone a resection for curative intent. Although such patients generally enjoy a favorable prognosis compared to patients diagnosed with unresectable disease, they remain at high risk of recurrence and death from the disease. Thus, we recently examined, among 1,279 patients with established Stage I, II, III colorectal cancers enrolled in the NHS and HPFS, whether aspirin use can influence prognosis. We found that use of aspirin after diagnosis of colorectal cancer is associated with improved survival from the disease. Compared with non-users, participants who regularly used aspirin after diagnosis had a 29% reduction in colorectal-cancer specific mortality and a 21% reduction of overall mortality. Regular aspirin use after diagnosis was associated with a particularly low risk of colorectal-cancer specific mortality among participants in whom primary tumors overexpressed COX-2. Therefore, aspirin might influence the biology of established colorectal tumors, in addition to preventing their occurrence. Moreover, COX-2 or related markers might be used to determine which patients with newly diagnosed colorectal cancer are most likely to respond to anti-COX-2 directed therapies.367 A study performed in women with colorectal cancer also supports an effect of NSAIDs on survival.368 Nonetheless, randomized trials are needed to confirm these results before routine clinical recommendations can be implemented.

In summary, aspirin and COX-2 selective inhibitors reduce the risk of colorectal neoplasia. Presently, their routine use is not recommended for prevention of colorectal cancer in the general population due to concern about their associated toxicities. However, there are specific populations in which the potential benefit associated with their use may outweigh the risks.

Post-Menopausal Hormones

Differences in sex hormones might account for the fact that the ratio of women to men with colorectal cancer is lower before age 50–54 years (i.e. for premenopausal women) than after (i.e. for postmenopausal women).369370 This observation stimulated research into whether postmenopausal hormones reduce risk of colorectal cancer. Estrogens have been proposed to alter bile acid composition, modulate colonic transit,371 and decrease production of mitogenic insulin-like growth factor-1.372 Colorectal epithelium expresses estrogen receptors, which might be modulated by age-related promoter hypermethylation.373 Colon cancers also express estrogen receptor-β, which might modulate the effect of exogenous estrogens on tumor growth. With a few exceptions,374376 most prospective studies show an inverse association between use of postmenopausal hormones and risk of colorectal cancer. 239377393 Similarly, most studies have also shown an inverse association between postmenopausal hormone use and risk of colorectal adenoma.394398 Based on data from the NHS, postmenopausal hormone use was associated with a decreased risk of colorectal cancer (multivariate RR, 0.65; 95% CI, 0.50–0.83) and large colorectal adenoma (≥ 1cm in diameter) (multivariate RR, 0.74, 95% CI, 0.55–0.99).399 These results were confirmed in a 2 separate meta-analyses of epidemiological studies.400401

These observational results were subsequently confirmed in the WHI estrogen plus progestin randomized, placebo-controlled trial conducted among nearly 17,000 post-menopausal women. In that trial, after a mean of 5.2 years of follow-up, estrogen and progestin were associated with a 37% reduction in colorectal cancer risk, comparable with the results from prospective, observational studies. However, these results were tempered by a finding that colorectal cancers in women who were given estrogen plus progestin were diagnosed at a more advanced stage than those of patients that received placebo.402 In contrast, the WHI estrogen-alone trial did not show any benefit for colorectal cancer.403 This is in agreement with most observational studies that have also shown an inverse association between colorectal cancer and the combination of estrogen plus progestin, but not for estrogen-alone.388404405 Of note, one recent study did observe that long duration estrogen-alone therapy but not estrogen plus progestin is associated with lower risk of colorectal cancer.406

In summary, although postmenopausal hormone therapy appears to be associated with a lower risk of colorectal cancer, it remains unclear which preparations of estrogen-alone or estrogen plus progestin are optimal. Moreover, because postmenopausal hormones increase the risk of breast cancer and cardiovascular events,402 the associated balance of risks and benefits do not support a recommendation of use of postmenopausal hormones as a means of preventing colorectal cancer.407

The Overall Potential of Primary Prevention

Based on the dietary, lifestyle, and medication risk factors we have outlined, there is substantial potential for primary prevention of colorectal cancer through modification of several environmental influences. For dietary factors, although controversy exists regarding the role of specific nutritional elements, consideration of the dietary pattern as a whole might be useful for formulating recommendations. For example, several studies have shown that high intake of red and processed meats, high-fat dairy products, highly refined grains and starches, and sugars are related to a higher risk of colon cancer. Thus, replacing these factors with poultry, fish and plant sources as the primary source of protein; mono-unsaturated, and poly-unsaturated fats as the primary source of fat; and unrefined grains, legumes and fruits as the primary source of carbohydrates is likely to lower risk of colorectal cancer. This benefit is likely to be sustained irrespective of whether the independent benefit of each component or their precise anti-cancer mechanisms is established. Although the role for many supplements, including vitamin D, folate, and B6, remains largely uncertain, calcium supplementation is likely at least modestly beneficial, particularly in those with low intake of dietary calcium. Vitamin D intakes of 1000–2000 IU/day might improve overall health status and possibly lower risk of colorectal cancer.

For lifestyle factors, there is compelling evidence that avoidance of smoking and heavy alcohol use, prevention of weight gain, and the maintenance of a reasonable level of physical activity can each have a positive influence on risk of colorectal cancer. In addition, there is strong evidence that medications such as aspirin and NSAIDs are effective chemopreventive drugs. Certain preparations of postmenopausal hormones might also be associated with lower risk of colorectal cancer. Although none of these agents are recommended for widespread primary prevention due to their side effect profile, they provide proof-of-principle of the potential to translate epidemiological findings into clinically efficacious chemopreventive drug interventions.

Taken together, modification of multiple diet and lifestyle factors is likely to have a substantial overall impact on risk of colorectal cancer. In a previous study of the HPFS, as many as 70% of the overall burden of colon cancers in the U.S. population could be prevented through moderate changes in diet and lifestyle.408 Using population-based projections, a separate study reached similar conclusions, albeit with more modest estimates of benefit.409 To further integrate the combined effect of modifiable risk factors, we recently developed a comprehensive model of colon cancer incidence that accounted for changes in the influence of risk factors throughout the lifespan. We found that women with profiles of modifiable lifestyle factors that were “high risk” had a nearly 4-fold higher risk of colon cancer compared with women with “low-risk” profiles (Figure 4).410 Although endoscopic screening could reduce cancer incidence among these high-risk women, their risk remained significantly higher than women whose lifestyle behaviors placed them in the moderate- or low-risk categories (Figure 5). Thus, primary prevention of colorectal cancer through lifestyle changes is an important complement to colorectal cancer screening in reducing colon cancer incidence. Moreover, because many diet and lifestyle risk factors for colorectal cancer overlap with other chronic illnesses, including cardiovascular disease, further research into these risk factors would have benefits beyond prevention of colorectal cancer.

An external file that holds a picture, illustration, etc.
Object name is nihms233908f4.jpg
Age-specific incidence of colon cancer per 100,000 person-years according to modifiable risk factors

Women were enrolled in the Nurses’ Health Study and were followed between 1980 and 2004. Women were assumed to have no postmenopausal hormone use, no aspirin use, average height, no family history of colorectal cancer, and have never been screened for colorectal cancer. 1) a "high-risk" participant (one who accrued 10 pack-years of smoking before age 30 years, had a consistently high relative body weight, had physical activity of 2 metabolic equivalent (MET)-hours/week, consumed 1 serving of red or processed meat per day, and had a folate intake of 150 µg/day); 2) a "moderate-risk" participant (one who was a nonsmoker, had an average body mass index, had physical activity of 13.5 MET-hours/week, did not consume red or processed meat, and had a folate intake of 300 µg/day); and 3) a "low-risk" participant (one who was a nonsmoker, had a consistently low relative body weight, had physical activity of 21 MET-hours/week, did not consume red or processed meat, and had a folate intake of 400 µg/day). Taken from Wei et al.410

An external file that holds a picture, illustration, etc.
Object name is nihms233908f5.jpg
Age-specific incidence of colon cancer per 100,000 person-years according to modifiable risk factors and screening behavior

Women were enrolled in the Nurses’ Health Study and were followed between 1980 and 2004. Women were assumed to have no postmenopausal hormone use, no aspirin use, average height, no family history of colorectal cancer, and have never been screened for colorectal cancer. 1) a high-risk" participant (one who accrued 10 pack-years of smoking before age 30 years, had a consistently high relative body weight, had physical activity of 2 metabolicMET)-hours/week, consumed 1 serving of red or processed meat per day, was never screened for colon cancer, and had a folate intake of 150 µg/day); 2) a high-risk participant who was screened from age 50 years to age 70 years; 3) a "moderate-risk" participant (one who was a nonsmoker, had an average body mass index, had physical activity of 13.5 MET-hours/week, did not consume red or processed meat, was never screened, and had a folate intake of 300 µg/day); and 4) a “low-risk” participant (one who was a nonsmoker, had a consistently low relative body weight, had physical activity of 21 MET-hours/week, did not consume red or processed meat, was never screened, and had a folate intake of 400 µg/day). Taken from Wei et al.410

Acknowledgments

Funding: Supported by funds from the National Cancer Institute: {"type":"entrez-nucleotide","attrs":{"text":"CA107412","term_id":"34960719","term_text":"CA107412"}}CA107412 and {"type":"entrez-nucleotide","attrs":{"text":"CA137178","term_id":"35026909","term_text":"CA137178"}}CA137178 (to ATC); CA 055075, {"type":"entrez-nucleotide","attrs":{"text":"CA087969","term_id":"34941276","term_text":"CA087969"}}CA087969, {"type":"entrez-nucleotide","attrs":{"text":"CA133891","term_id":"35020338","term_text":"CA133891"}}CA133891 (to ELG). Dr. Chan is a Damon Runyon Cancer Foundation Clinical Investigator.

Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School (ATC); Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School (ATC and ELG); Departments of Nutrition and Epidemiology, Harvard School of Public Health (ELG)
Correspondence to: Andrew T. Chan, M.D., M.P.H., Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, GRJ-722, Boston, MA 02114, Tel: 617 726 3212, Fax: 617 726 3673, gro.srentrap@nahca
Publisher's Disclaimer

Abstract

Colorectal cancer has been strongly associated with a Western lifestyle. In the past several decades, much has been learned about the dietary, lifestyle, and medication risk factors for this malignancy. Although there is controversy about the role of specific nutritional factors, consideration of the dietary pattern as a whole appears useful for formulating recommendations. For example, several studies have shown that high intake of red and processed meats, highly refined grains and starches, and sugars is related to increased risk of colorectal cancer. Replacing these factors with poultry, fish, and plant sources as the primary source of protein; unsaturated fats as the primary source of fat; and unrefined grains, legumes and fruits as the primary source of carbohydrates is likely to lower risk of colorectal cancer. Although a role for supplements, including vitamin D, folate, and vitamin B6, remains uncertain, calcium supplementation is likely to be at least modestly beneficial. With respect to lifestyle, compelling evidence indicates that avoidance of smoking and heavy alcohol use, prevention of weight gain, and the maintenance of a reasonable level of physical activity are associated with markedly lower risks of colorectal cancer. Medications such as aspirin and non-steroidal anti-inflammatory drugs and post-menopausal hormones for women are associated with significant reductions in colorectal cancer risk, though their utility is affected by associated risks. Taken together, modifications in diet and lifestyle should substantially reduce the risk of colorectal cancer and could complement screening in reducing colorectal cancer incidence.

Abstract

Biographies

An external file that holds a picture, illustration, etc.
Object name is nihms233908b1.gif

An external file that holds a picture, illustration, etc.
Object name is nihms233908b2.gif

Biographies

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Financial Disclosures: No conflicts of interest exist.

Author Contributions: Each author was directly involved with drafting of the manuscript; critical revision of the manuscript for important intellectual content; obtaining funding.

Footnotes

REFERENCES

REFERENCES

References

  • 1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Society; 2009. [PubMed]
  • 2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P IARC Scientific Publications No. 160. Vol. IX. Lyon: IARC; 2007. Cancer incidence in five continents. [PubMed][Google Scholar]
  • 3. Parkin DM, Bray F, Ferlay J, Pisani PGlobal cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.[PubMed][Google Scholar]
  • 4. Giovannucci E, Willett WCDietary factors and risk of colon cancer. Ann Med. 1994;26:443–452.[PubMed][Google Scholar]
  • 5. Burkitt DPRelated disease--related cause? Lancet. 1969;2:1229–1231.[PubMed][Google Scholar]
  • 6. Kritchevsky DEpidemiology of fibre, resistant starch and colorectal cancer. Eur J Cancer Prev. 1995;4:345–352.[PubMed][Google Scholar]
  • 7. Levi F, Pasche C, Lucchini F, La Vecchia CDietary fibre and the risk of colorectal cancer. Eur J Cancer. 2001;37:2091–2096.[PubMed][Google Scholar]
  • 8. Trock B, Lanza E, Greenwald PDietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. J Natl Cancer Inst. 1990;82:650–661.[PubMed][Google Scholar]
  • 9. Howe GR, Benito E, Castelleto R, Cornee J, Esteve J, Gallagher RP, Iscovich JM, Deng-ao J, Kaaks R, Kune GA, et al Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst. 1992;84:1887–1896.[PubMed][Google Scholar]
  • 10. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FERelation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323:1664–1672.[PubMed][Google Scholar]
  • 11. Goldbohm RA, van den Brandt PA, van 't Veer P, Brants HA, Dorant E, Sturmans F, Hermus RJA prospective cohort study on the relation between meat consumption and the risk of colon cancer. Cancer Res. 1994;54:718–723.[PubMed][Google Scholar]
  • 12. Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, Gapstur SM, Folsom ARSugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States) Cancer Causes Control. 1994;5:38–52.[PubMed][Google Scholar]
  • 13. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, Speizer FE, Willett WCDietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340:169–176.[PubMed][Google Scholar]
  • 14. Michels KB, Giovannucci E, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS, Colditz GA, Speizer FE, Willett WCProspective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst. 2000;92:1740–1752.[PubMed][Google Scholar]
  • 15. Pietinen P, Malila N, Virtanen M, Hartman TJ, Tangrea JA, Albanes D, Virtamo JDiet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control. 1999;10:387–396.[PubMed][Google Scholar]
  • 16. Park Y, Hunter DJ, Spiegelman D, Bergkvist L, Berrino F, van den Brandt PA, Buring JE, Colditz GA, Freudenheim JL, Fuchs CS, Giovannucci E, Goldbohm RA, Graham S, Harnack L, Hartman AM, Jacobs DR, Jr, Kato I, Krogh V, Leitzmann MF, McCullough ML, Miller AB, Pietinen P, Rohan TE, Schatzkin A, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SADietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. Jama. 2005;294:2849–2857.[PubMed][Google Scholar]
  • 17. Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van den Brandt PA, Buring JE, Calle EE, Cho E, Fraser GE, Freudenheim JL, Fuchs CS, Giovannucci EL, Goldbohm RA, Harnack L, Jacobs DR, Jr, Kato I, Krogh V, Larsson SC, Leitzmann MF, Marshall JR, McCullough ML, Miller AB, Pietinen P, Rohan TE, Schatzkin A, Sieri S, Virtanen MJ, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SAFruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst. 2007;99:1471–1483.[PubMed][Google Scholar]
  • 18. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, Clavel-Chapelon F, Kesse E, Nieters A, Boeing H, Tjonneland A, Overvad K, Martinez C, Dorronsoro M, Gonzalez CA, Key TJ, Trichopoulou A, Naska A, Vineis P, Tumino R, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Berglund G, Hallmans G, Lund E, Skeie G, Kaaks R, Riboli EDietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet. 2003;361:1496–1501.[PubMed][Google Scholar]
  • 19. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, Casagrande C, Tjonneland A, Olsen A, Overvad K, Thorlacius-Ussing O, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Linseisen J, Boeing H, Nothlings U, Trichopoulou A, Trichopoulos D, Misirli G, Palli D, Sieri S, Panico S, Tumino R, Vineis P, Peeters PH, van Gils CH, Ocke MC, Lund E, Engeset D, Skeie G, Suarez LR, Gonzalez CA, Sanchez MJ, Dorronsoro M, Navarro C, Barricarte A, Berglund G, Manjer J, Hallmans G, Palmqvist R, Bingham SA, Khaw KT, Key TJ, Allen NE, Boffetta P, Slimani N, Rinaldi S, Gallo V, Norat T, Riboli EFruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2009;89:1441–1452.[PubMed][Google Scholar]
  • 20. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342:1149–1155.[PubMed]
  • 21. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, Earnest DL, Sampliner RE. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med. 2000;342:1156–1162.[PubMed]
  • 22. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 2000;356:1300–1306.[PubMed]
  • 23. Le Leu RK, Brown IL, Hu Y, Esterman A, Young GPSuppression of azoxymethane-induced colon cancer development in rats by dietary resistant starch. Cancer Biol Ther. 2007;6:1621–1626.[PubMed][Google Scholar]
  • 24. Le Leu RK, Brown IL, Hu Y, Morita T, Esterman A, Young GPEffect of dietary resistant starch and protein on colonic fermentation and intestinal tumourigenesis in rats. Carcinogenesis. 2007;28:240–245.[PubMed][Google Scholar]
  • 25. Dronamraju SS, Coxhead JM, Kelly SB, Burn J, Mathers JCCell kinetics and gene expression changes in colorectal cancer patients given resistant starch: a randomised controlled trial. Gut. 2009;58:413–420.[PubMed][Google Scholar]
  • 26. Young GP, Le Leu RKResistant starch and colorectal neoplasia. J AOAC Int. 2004;87:775–786.[PubMed][Google Scholar]
  • 27. Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JCEffect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359:2567–2578.[PubMed][Google Scholar]
  • 28. Benito E, Cabeza E, Moreno V, Obrador A, Bosch FXDiet and colorectal adenomas: a case-control study in Majorca. Int J Cancer. 1993;55:213–219.[PubMed][Google Scholar]
  • 29. Benito E, Obrador A, Stiggelbout A, Bosch FX, Mulet M, Muñoz N, Kaldor J. A population-based case-control study of colorectal cancer in Majorca. I. Dietary factors. Int J Cancer. 1990;45:69–76.[PubMed]
  • 30. Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, Rodriguez C, Sinha R, Calle EEMeat consumption and risk of colorectal cancer. Jama. 2005;293:172–182.[PubMed][Google Scholar]
  • 31. Cross AJ, Leitzmann MF, Gail MH, Hollenbeck AR, Schatzkin A, Sinha RA prospective study of red and processed meat intake in relation to cancer risk. PLoS Med. 2007;4:e325.[Google Scholar]
  • 32. English DR, MacInnis RJ, Hodge AM, Hopper JL, Haydon AM, Giles GGRed meat, chicken, and fish consumption and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1509–1514.[PubMed][Google Scholar]
  • 33. Gaard M, Tretli S, Loken EBDietary factors and risk of colon cancer: a prospective study of 50,535 young Norwegian men and women. Eur J Cancer Prev. 1996;5:445–454.[PubMed][Google Scholar]
  • 34. Gerhardsson de Verdier M, Hagman U, Peters RK, Steineck G, Overvik EMeat, cooking methods and colorectal cancer: a case-referent study in Stockholm. Int J Cancer. 1991;49:520–525.[PubMed][Google Scholar]
  • 35. Giovannucci E, Stampfer MJ, Colditz G, Rimm EB, Willett WCRelationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst. 1992;84:91–98.[PubMed][Google Scholar]
  • 36. Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk ARed meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish Mammography Cohort. Int J Cancer. 2005;113:829–834.[PubMed][Google Scholar]
  • 37. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NEColorectal cancer and diet in an Asian population--a case-control study among Singapore Chinese. Int J Cancer. 1989;43:1007–1016.[PubMed][Google Scholar]
  • 38. Martinez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, Thompson PAMeat intake, preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis. 2007;28:2019–2027.[PubMed][Google Scholar]
  • 39. Neugut AI, Garbowski GC, Lee WC, Murray T, Nieves JW, Forde KA, Treat MR, Waye JD, Fenoglio-Preiser C. Dietary risk factors for the incidence and recurrence of colorectal adenomatous polyps. A case-control study. Ann Intern Med. 1993;118:91–95.[PubMed]
  • 40. Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, Overvad K, Olsen A, Tjonneland A, Clavel F, Boutron-Ruault MC, Kesse E, Boeing H, Bergmann MM, Nieters A, Linseisen J, Trichopoulou A, Trichopoulos D, Tountas Y, Berrino F, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Engeset D, Lund E, Skeie G, Ardanaz E, Gonzalez C, Navarro C, Quiros JR, Sanchez MJ, Berglund G, Mattisson I, Hallmans G, Palmqvist R, Day NE, Khaw KT, Key TJ, San Joaquin M, Hemon B, Saracci R, Kaaks R, Riboli EMeat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97:906–916.[Google Scholar]
  • 41. Shin A, Shrubsole MJ, Ness RM, Wu H, Sinha R, Smalley WE, Shyr Y, Zheng WMeat and meat-mutagen intake, doneness preference and the risk of colorectal polyps: the Tennessee Colorectal Polyp Study. Int J Cancer. 2007;121:136–142.[PubMed][Google Scholar]
  • 42. Steinmetz KA, Potter JD. Food-group consumption and colon cancer in the Adelaide Case-Control Study. II. Meat, poultry, seafood, dairy foods and eggs. Int J Cancer. 1993;53:720–727.[PubMed]
  • 43. Stemmermann GN, Nomura AM, Heilbrun LKDietary fat and the risk of colorectal cancer. Cancer Res. 1984;44:4633–4637.[PubMed][Google Scholar]
  • 44. Young TB, Wolf DACase-control study of proximal and distal colon cancer and diet in Wisconsin. Int J Cancer. 1988;42:167–175.[PubMed][Google Scholar]
  • 45. Norat T, Lukanova A, Ferrari P, Riboli EMeat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer. 2002;98:241–256.[PubMed][Google Scholar]
  • 46. Robertson DJ, Sandler RS, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JAFat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol. 2005;100:2789–2795.[PubMed][Google Scholar]
  • 47. Sandhu MS, White IR, McPherson KSystematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev. 2001;10:439–446.[PubMed][Google Scholar]
  • 48. Bird CL, Witte JS, Swendseid ME, Shikany JM, Hunt IF, Frankl HD, Lee ER, Longnecker MP, Haile RWPlasma ferritin, iron intake, and the risk of colorectal polyps. Am J Epidemiol. 1996;144:34–41.[PubMed][Google Scholar]
  • 49. Nelson RL, Davis FG, Sutter E, Sobin LH, Kikendall JW, Bowen PBody iron stores and risk of colonic neoplasia. J Natl Cancer Inst. 1994;86:455–460.[PubMed][Google Scholar]
  • 50. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, Galanko J, Sandler RSAssociation between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95:154–159.[PubMed][Google Scholar]
  • 51. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RBIron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:503–507.[PubMed][Google Scholar]
  • 52. Lee DH, Anderson KE, Harnack LJ, Folsom AR, Jacobs DR., Jr Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. J Natl Cancer Inst. 2004;96:403–407.[PubMed]
  • 53. Tseng M, Greenberg ER, Sandler RS, Baron JA, Haile RW, Blumberg BS, McGlynn KASerum ferritin concentration and recurrence of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2000;9:625–630.[PubMed][Google Scholar]
  • 54. Tseng M, Sandler RS, Greenberg ER, Mandel JS, Haile RW, Baron JADietary iron and recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1997;6:1029–1032.[PubMed][Google Scholar]
  • 55. Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, Fuchs CSHemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst. 2005;97:917–926.[PubMed][Google Scholar]
  • 56. Probst-Hensch NM, Sinha R, Longnecker MP, Witte JS, Ingles SA, Frankl HD, Lee ER, Haile RWMeat preparation and colorectal adenomas in a large sigmoidoscopy-based case-control study in California (United States) Cancer Causes Control. 1997;8:175–183.[PubMed][Google Scholar]
  • 57. Sinha R, Chow WH, Kulldorff M, Denobile J, Butler J, Garcia-Closas M, Weil R, Hoover RN, Rothman NWell-done, grilled red meat increases the risk of colorectal adenomas. Cancer Res. 1999;59:4320–4324.[PubMed][Google Scholar]
  • 58. Sugimura TCarcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res. 1985;150:33–41.[PubMed][Google Scholar]
  • 59. Sugimura TOverview of carcinogenic heterocyclic amines. Mutat Res. 1997;376:211–219.[PubMed][Google Scholar]
  • 60. Wakabayashi K, Nagao M, Esumi H, Sugimura TFood-derived mutagens and carcinogens. Cancer Res. 1992;52 2092s–2098s. [[PubMed][Google Scholar]
  • 61. Ferrucci LM, Sinha R, Graubard BI, Mayne ST, Ma X, Schatzkin A, Schoenfeld PS, Cash BD, Flood A, Cross AJDietary meat intake in relation to colorectal adenoma in asymptomatic women. Am J Gastroenterol. 2009;104:1231–1240.[Google Scholar]
  • 62. Gunter MJ, Probst-Hensch NM, Cortessis VK, Kulldorff M, Haile RW, Sinha RMeat intake, cooking-related mutagens and risk of colorectal adenoma in a sigmoidoscopy-based case-control study. Carcinogenesis. 2005;26:637–642.[PubMed][Google Scholar]
  • 63. Ishibe N, Sinha R, Hein DW, Kulldorff M, Strickland P, Fretland AJ, Chow WH, Kadlubar FF, Lang NP, Rothman NGenetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics. 2002;12:145–150.[PubMed][Google Scholar]
  • 64. Kampman E, Slattery ML, Bigler J, Leppert M, Samowitz W, Caan BJ, Potter JDMeat consumption, genetic susceptibility, and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol Biomarkers Prev. 1999;8:15–24.[PubMed][Google Scholar]
  • 65. Le Marchand L, Hankin JH, Pierce LM, Sinha R, Nerurkar PV, Franke AA, Wilkens LR, Kolonel LN, Donlon T, Seifried A, Custer LJ, Lum-Jones A, Chang WWell-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutat Res. 2002;506–507:205–214.[PubMed][Google Scholar]
  • 66. Nowell S, Coles B, Sinha R, MacLeod S, Luke Ratnasinghe D, Stotts C, Kadlubar FF, Ambrosone CB, Lang NPAnalysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. Mutat Res. 2002;506–507:175–185.[PubMed][Google Scholar]
  • 67. Sinha R, Kulldorff M, Chow WH, Denobile J, Rothman NDietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2001;10:559–562.[PubMed][Google Scholar]
  • 68. Sinha R, Kulldorff M, Gunter MJ, Strickland P, Rothman NDietary benzo[a]pyrene intake and risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:2030–2034.[PubMed][Google Scholar]
  • 69. Sinha R, Peters U, Cross AJ, Kulldorff M, Weissfeld JL, Pinsky PF, Rothman N, Hayes RBMeat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res. 2005;65:8034–8041.[PubMed][Google Scholar]
  • 70. Wu K, Giovannucci E, Byrne C, Platz EA, Fuchs C, Willett WC, Sinha R. Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men. Cancer Epidemiol Biomarkers Prev. 2006;15:1120–1125.[PubMed]
  • 71. Gunter MJ, Divi RL, Kulldorff M, Vermeulen R, Haverkos KJ, Kuo MM, Strickland P, Poirier MC, Rothman N, Sinha RLeukocyte polycyclic aromatic hydrocarbon-DNA adduct formation and colorectal adenoma. Carcinogenesis. 2007;28:1426–1429.[PubMed][Google Scholar]
  • 72. Peters U, DeMarini DM, Sinha R, Brooks LR, Warren SH, Chatterjee N, Rothman NUrinary mutagenicity and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2003;12:1253–1256.[PubMed][Google Scholar]
  • 73. Butler LM, Millikan RC, Sinha R, Keku TO, Winkel S, Harlan B, Eaton A, Gammon MD, Sandler RSModification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. Mutat Res. 2008;638:162–174.[Google Scholar]
  • 74. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willett WC, Hennekens CH, Kelsey KT, Hunter DJA prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res. 1998;58:3307–3311.[PubMed][Google Scholar]
  • 75. Joshi AD, Corral R, Siegmund KD, Haile RW, Le Marchand L, Martinez ME, Ahnen DJ, Sandler RS, Lance P, Stern MCRed meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. Carcinogenesis. 2009;30:472–479.[Google Scholar]
  • 76. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FFRapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev. 1994;3:675–682.[PubMed][Google Scholar]
  • 77. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, Seifried A, Custer LJ, Chang W, Lum-Jones A, Donlon TCombined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:1259–1266.[PubMed][Google Scholar]
  • 78. Probst-Hensch NM, Haile RW, Ingles SA, Longnecker MP, Han CY, Lin BK, Lee DB, Sakamoto GT, Frankl HD, Lee ER, et al Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res. 1995;55:2017–2020.[PubMed][Google Scholar]
  • 79. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ, Butler RNDiet, acetylator phenotype, and risk of colorectal neoplasia. Lancet. 1996;347:1372–1374.[PubMed][Google Scholar]
  • 80. Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, Smalley WE, Shyr Y, Sinha R, Ness RM, Hein DW, Zheng WMeat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev. 2008;17:320–329.[Google Scholar]
  • 81. Chan AT, Tranah GJ, Giovannucci EL, Willett WC, Hunter DJ, Fuchs CSProspective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. Int J Cancer. 2005;115:648–652.[PubMed][Google Scholar]
  • 82. Chiu BC, Ji BT, Dai Q, Gridley G, McLaughlin JK, Gao YT, Fraumeni JF, Jr, Chow WHDietary factors and risk of colon cancer in shanghai, china. Cancer Epidemiol Biomarkers Prev. 2003;12:201–208.[PubMed][Google Scholar]
  • 83. Kato I, Akhmedkhanov A, Koenig K, Toniolo PG, Shore RE, Riboli EProspective study of diet and female colorectal cancer: the New York University Women's Health Study. Nutrition and Cancer. 1997;28:276–281.[PubMed][Google Scholar]
  • 84. Geelen A, Schouten JM, Kamphuis C, Stam BE, Burema J, Renkema JM, Bakker EJ, van't Veer P, Kampman EFish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am J Epidemiol. 2007;166:1116–1125.[PubMed][Google Scholar]
  • 85. Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma JBlood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:314–321.[PubMed][Google Scholar]
  • 86. Hall MN, Chavarro JE, Lee IM, Willett WC, Ma JA 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev. 2008;17:1136–1143.[Google Scholar]
  • 87. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk ADietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935–945.[PubMed][Google Scholar]
  • 88. Oh K, Willett WC, Fuchs CS, Giovannucci EDietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2005;14:835–841.[PubMed][Google Scholar]
  • 89. Daniel CR, McCullough ML, Patel RC, Jacobs EJ, Flanders WD, Thun MJ, Calle EE. Dietary intake of omega-6 and omega-3 fatty acids and risk of colorectal cancer in a prospective cohort of U.S. men and women. Cancer Epidemiol Biomarkers Prev. 2009;18:516–525.[PubMed]
  • 90. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FBConsumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004;134:1806–1811.[PubMed][Google Scholar]
  • 91. Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu TCyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 2008;68:553–560.[PubMed][Google Scholar]
  • 92. Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, Kang JXColitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis. 2007;28:1991–1995.[PubMed][Google Scholar]
  • 93. Benito E, Stiggelbout A, Bosch FX, Obrador A, Kaldor J, Mulet M, Munoz NNutritional factors in colorectal cancer risk: a case-control study in Majorca. Int J Cancer. 1991;49:161–167.[PubMed][Google Scholar]
  • 94. Freudenheim JL, Graham S, Marshall JR, Haughey BP, Wilkinson GA case-control study of diet and rectal cancer in western New York. Am J Epidemiol. 1990;131:612–624.[PubMed][Google Scholar]
  • 95. Franceschi S, Dal Maso L, Augustin L, Negri E, Parpinel M, Boyle P, Jenkins DJ, La Vecchia CDietary glycemic load and colorectal cancer risk. Ann Oncol. 2001;12:173–178.[PubMed][Google Scholar]
  • 96. Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve PGlycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr. 2008;87:1793–1801.[PubMed][Google Scholar]
  • 97. Higginbotham S, Zhang ZF, Lee IM, Cook NR, Giovannucci E, Buring JE, Liu SDietary glycemic load and risk of colorectal cancer in the Women's Health Study. J Natl Cancer Inst. 2004;96:229–233.[Google Scholar]
  • 98. McCarl M, Harnack L, Limburg PJ, Anderson KE, Folsom ARIncidence of colorectal cancer in relation to glycemic index and load in a cohort of women. Cancer Epidemiol Biomarkers Prev. 2006;15:892–896.[PubMed][Google Scholar]
  • 99. Michaud DS, Fuchs CS, Liu S, Willett WC, Colditz GA, Giovannucci EDietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2005;14:138–147.[PubMed][Google Scholar]
  • 100. Flood A, Peters U, Jenkins DJ, Chatterjee N, Subar AF, Church TR, Bresalier R, Weissfeld JL, Hayes RB, Schatzkin ACarbohydrate, glycemic index, and glycemic load and colorectal adenomas in the Prostate, Lung, Colorectal, and Ovarian Screening Study. Am J Clin Nutr. 2006;84:1184–1192.[PubMed][Google Scholar]
  • 101. Howarth NC, Murphy SP, Wilkens LR, Henderson BE, Kolonel LNThe association of glycemic load and carbohydrate intake with colorectal cancer risk in the Multiethnic Cohort Study. Am J Clin Nutr. 2008;88:1074–1082.[Google Scholar]
  • 102. Kabat GC, Shikany JM, Beresford SA, Caan B, Neuhouser ML, Tinker LF, Rohan TEDietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women's Health Initiative. Cancer Causes Control. 2008;19:1291–1298.[Google Scholar]
  • 103. Larsson SC, Giovannucci E, Wolk ADietary carbohydrate, glycemic index, and glycemic load in relation to risk of colorectal cancer in women. Am J Epidemiol. 2007;165:256–261.[PubMed][Google Scholar]
  • 104. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MMGlycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. Am J Clin Nutr. 2009;89:568–576.[PubMed][Google Scholar]
  • 105. Oh K, Willett WC, Fuchs CS, Giovannucci ELGlycemic index, glycemic load, and carbohydrate intake in relation to risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2004;13:1192–1198.[PubMed][Google Scholar]
  • 106. Strayer L, Jacobs DR, Jr, Schairer C, Schatzkin A, Flood ADietary carbohydrate, glycemic index, and glycemic load and the risk of colorectal cancer in the BCDDP cohort. Cancer Causes Control. 2007;18:853–863.[PubMed][Google Scholar]
  • 107. Weijenberg MP, Mullie PF, Brants HA, Heinen MM, Goldbohm RA, van den Brandt PADietary glycemic load, glycemic index and colorectal cancer risk: results from the Netherlands Cohort Study. Int J Cancer. 2008;122:620–629.[PubMed][Google Scholar]
  • 108. Newmark HL, Wargovich MJ, Bruce WRColon cancer and dietary fat, phosphate, and calcium: a hypothesis. Journal of the National Cancer Institute. 1984;72:1323–1325.[PubMed][Google Scholar]
  • 109. van der Meer R, de Vries HTDifferential binding of glycine- and taurine-conjugated bile acids to insoluble calcium phosphate. Biochem J. 1985;229:265–268.[Google Scholar]
  • 110. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V, Dash CEffects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila Pa) 2009;2:213–223.[Google Scholar]
  • 111. Fedirko V, Bostick RM, Flanders WD, Long Q, Sidelnikov E, Shaukat A, Daniel CR, Rutherford RE, Woodard JJEffects of Vitamin D and Calcium on Proliferation and Differentiation In Normal Colon Mucosa: a Randomized Clinical Trial. Cancer Epidemiol Biomarkers Prev. 2009[Google Scholar]
  • 112. Lipkin M, Newmark HEffect of added dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer. New England Journal of Medicine. 1985;313:1381–1384.[PubMed][Google Scholar]
  • 113. Martinez ME, Willett WCCalcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 1998;7:163–168.[PubMed][Google Scholar]
  • 114. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci ELCalcium intake and risk of colon cancer in women and men. J Natl Cancer Inst. 2002;94:437–446.[PubMed][Google Scholar]
  • 115. Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, Colditz GA, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Pietinen P, Potter JD, Rohan TE, Terry P, Toniolo P, Virtanen MJ, Willett WC, Wolk A, Wu K, Yaun SS, Zeleniuch-Jacquotte A, Hunter DJDairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004;96:1015–1022.[PubMed][Google Scholar]
  • 116. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999;340:101–107.[PubMed]
  • 117. Wallace K, Baron JA, Cole BF, Sandler RS, Karagas MR, Beach MA, Haile RW, Burke CA, Pearson LH, Mandel JS, Rothstein R, Snover DCEffect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst. 2004;96:921–925.[PubMed][Google Scholar]
  • 118. Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JSProlonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst. 2007;99:129–136.[PubMed][Google Scholar]
  • 119. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, Heber DVitamin D, Calcium Supplementation, and Colorectal Adenomas: Results of a Randomized Trial. J Natl Cancer Inst. 2003;95:1765–1771.[PubMed][Google Scholar]
  • 120. Garland CF, Garland FCDo Sunlight and Vitamin D Reduce the Likelihood of Colon Cancer? Int. J. Epidemiol. 1980;9:227–231. %R 10.1093/ije/9.3.227. [[PubMed][Google Scholar]
  • 121. Giovannucci EThe epidemiology of vitamin D and cancer incidence and mortality: a review (United States) Cancer Causes and Control. 2005;16:83–95.[PubMed][Google Scholar]
  • 122. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MTA crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386–2392.[PubMed][Google Scholar]
  • 123. Froicu M, Zhu Y, Cantorna MTVitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology. 2006;117:310–318.[Google Scholar]
  • 124. Cantorna MT, Munsick C, Bemiss C, Mahon BD1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 2000;130:2648–2652.[PubMed][Google Scholar]
  • 125. Fichera A, Little N, Dougherty U, Mustafi R, Cerda S, Li YC, Delgado J, Arora A, Campbell LK, Joseph L, Hart J, Noffsinger A, Bissonnette MA vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res. 2007;142:239–245.[PubMed][Google Scholar]
  • 126. Zhu Y, Mahon BD, Froicu M, Cantorna MTCalcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217–224.[PubMed][Google Scholar]
  • 127. Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HHThe BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test. 2004;8:417–420.[PubMed][Google Scholar]
  • 128. Gilman J, Shanahan F, Cashman KDAltered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1007–1016.[PubMed][Google Scholar]
  • 129. Lim WC, Hanauer SB, Li YCMechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:308–315.[PubMed][Google Scholar]
  • 130. Peterlik M, Cross HSVitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005;35:290–304.[PubMed][Google Scholar]
  • 131. Simmons JD, Mullighan C, Welsh KI, Jewell DPVitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211–214.[Google Scholar]
  • 132. Dietrich T, Nunn M, Dawson-Hughes B, Bischoff-Ferrari HAAssociation between serum concentrations of 25-hydroxyvitamin D and gingival inflammation. Am J Clin Nutr. 2005;82:575–580.[PubMed][Google Scholar]
  • 133. Dietrich T, Joshipura KJ, Dawson-Hughes B, Bischoff-Ferrari HAAssociation between serum concentrations of 25-hydroxyvitamin D3 and periodontal disease in the US population. Am J Clin Nutr. 2004;80:108–113.[PubMed][Google Scholar]
  • 134. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-court D, Aganna E, Price CP, Boucher BJCirculating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787–796.[PubMed][Google Scholar]
  • 135. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane SPlasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer. 2007;97:446–451.[Google Scholar]
  • 136. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GWColon cancer and serum vitamin D metabolite levels 10–17 years prior to diagnosis. American Journal of Epidemiology. 1995;142:608–611.[PubMed][Google Scholar]
  • 137. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EPlasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiology, Biomarkers and Prevention. 2004;13:1502–1508.[PubMed][Google Scholar]
  • 138. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham EDSerum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 1989;2:1176–1178.[PubMed][Google Scholar]
  • 139. Levine AJ, Harper JM, Ervin CM, Chen YH, Harmon E, Xue S, Lee ER, Frankel HD, Haile RWSerum 25-hydroxyvitamin D, dietary calcium in take, and distal colorectal adenoma risk. Nutrition and Cancer. 2001;39:35–41.[PubMed][Google Scholar]
  • 140. Peters U, McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M, Rothman N, Sinha RVitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiology, Biomarkers and Prevention. 2001;10:1267–1274.[PubMed][Google Scholar]
  • 141. Platz EA, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannucci EPlasma 1,25-dihydroxy-and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiology, Biomarkers and Prevention. 2000;9:1059–1065.[PubMed][Google Scholar]
  • 142. Tangrea J, Helzlsouer K, Pietinen P, Taylor P, Hollis B, Virtamo J, Albanes DSerum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes and Control. 1997;8:615–625.[PubMed][Google Scholar]
  • 143. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JECalcium plus vitamin D supplementation and the risk of colorectal cancer. New England Journal of Medicine. 2006;354:684–696.[PubMed][Google Scholar]
  • 144. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MFVitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005;97:179–194.[PubMed][Google Scholar]
  • 145. Martinez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, Wing A, Willett WCCalcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst. 1996;88:1375–1382.[PubMed][Google Scholar]
  • 146. Ding EL, Mehta S, Fawzi WW, Giovannucci ELInteraction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. Int J Cancer. 2007[PubMed][Google Scholar]
  • 147. Giovannucci EEpidemiologic studies of folate and colorectal neoplasia: a review. Journal of Nutrition. 2002;132 2350S–2355S. [[PubMed][Google Scholar]
  • 148. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJFolate intake and colorectal cancer risk: a meta-analytical approach. International Journal of Cancer. 2005;113:825–828.[PubMed][Google Scholar]
  • 149. Schernhammer ES, Ogino S, Fuchs CSFolate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology. 2008;135:770–780.[Google Scholar]
  • 150. Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, Chen K, Gemignani F, Keku T, Lima CS, Le Marchand L, Matsuo K, Moreno V, Plaschke J, Pufulete M, Thomas SB, Toffoli G, Wolf CR, Moore CG, Little JMeta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol. 2009;170:1207–1221.[Google Scholar]
  • 151. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KRAspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29–38.[PubMed][Google Scholar]
  • 152. Wu K, Platz EA, Willett WC, Fuchs CS, Selhub J, Rosner BA, Hunter DJ, Giovannucci EA randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr. 2009;90:1623–1631.[Google Scholar]
  • 153. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ERFolic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–2359.[PubMed][Google Scholar]
  • 154. Kim YIFolate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen. 2004;44:10–25.[PubMed][Google Scholar]
  • 155. Giovannucci E, Ogino SDNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst. 2005;97:1317–1319.[PubMed][Google Scholar]
  • 156. Ishihara J, Otani T, Inoue M, Iwasaki M, Sasazuki S, Tsugane SLow intake of vitamin B-6 is associated with increased risk of colorectal cancer in Japanese men. J Nutr. 2007;137:1808–1814.[PubMed][Google Scholar]
  • 157. Larsson SC, Giovannucci E, Wolk AVitamin B6 intake, alcohol consumption, and colorectal cancer: a longitudinal population-based cohort of women. Gastroenterology. 2005;128:1830–1837.[PubMed][Google Scholar]
  • 158. Le Marchand L, White KK, Nomura AM, Wilkens LR, Selhub JS, Tiirikainen M, Goodman MT, Murphy SP, Henderson BE, Kolonel LNPlasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18:2195–2201.[Google Scholar]
  • 159. Lee JE, Li H, Giovannucci E, Lee IM, Selhub J, Stampfer M, Ma JProspective study of plasma vitamin B6 and risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev. 2009;18:1197–1202.[Google Scholar]
  • 160. Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA, Porteous ME, Dunlop MG, Campbell HDietary vitamin B6 intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:171–182.[PubMed][Google Scholar]
  • 161. Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma JPlasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst. 2005;97:684–692.[PubMed][Google Scholar]
  • 162. Zhang SM, Moore SC, Lin J, Cook NR, Manson JE, Lee IM, Buring JEFolate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women. Am J Epidemiol. 2006;163:108–115.[Google Scholar]
  • 163. de Vogel S, Dindore V, van Engeland M, Goldbohm RA, van den Brandt PA, Weijenberg MPDietary folate, methionine, riboflavin, and vitamin B-6 and risk of sporadic colorectal cancer. J Nutr. 2008;138:2372–2378.[PubMed][Google Scholar]
  • 164. Heilbrun LK, Nomura A, Hankin JH, Stemmermann GNDiet and colorectal cancer with special reference to fiber intake. Int J Cancer. 1989;44:1–6.[PubMed][Google Scholar]
  • 165. Potter JD, McMichael AJDiet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst. 1986;76:557–569.[PubMed][Google Scholar]
  • 166. Stemmermann GN, Nomura AMY, Chyou PH, Yoshizawa CProspective study of alcohol intake and large bowel cancer. Digestive Diseases and Sciences. 1990;35:1414–1420.[PubMed][Google Scholar]
  • 167. Tseng M, Murray SC, Kupper LL, Sandler RSMicronutrients and the risk of colorectal adenomas. Am J Epidemiol. 1996;144:1005–1014.[PubMed][Google Scholar]
  • 168. Wu AH, Paganini-Hill A, Ross RK, Henderson BEAlcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer. 1987;55:687–694.[Google Scholar]
  • 169. van den Brandt PA, Goldbohm RA, van 't Veer P, Bode P, Dorant E, Hermus RJ, Sturmans FA prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst. 1993;85:224–229.[PubMed][Google Scholar]
  • 170. Wallace K, Byers T, Morris JS, Cole BF, Greenberg ER, Baron JA, Gudino A, Spate V, Karagas MRPrediagnostic serum selenium concentration and the risk of recurrent colorectal adenoma: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2003;12:464–467.[PubMed][Google Scholar]
  • 171. Bjelakovic G, Nikolova D, Simonetti RG, Gluud CAntioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364:1219–1228.[PubMed][Google Scholar]
  • 172. Clark LC, Hixson LJ, Combs GF, Jr, Reid ME, Turnbull BW, Sampliner REPlasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev. 1993;2:41–46.[PubMed][Google Scholar]
  • 173. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RSSelenium, apoptosis, and colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2006;15:486–493.[PubMed][Google Scholar]
  • 174. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez MESelenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst. 2004;96:1669–1675.[PubMed][Google Scholar]
  • 175. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, Schatzkin A, Hayes RBHigh serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev. 2006;15:315–320.[PubMed][Google Scholar]
  • 176. Reid ME, Duffield-Lillico AJ, Sunga A, Fakih M, Alberts DS, Marshall JRSelenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer. 2006;118:1777–1781.[PubMed][Google Scholar]
  • 177. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RSPlasma selenium levels and the risk of colorectal adenomas. Nutr Cancer. 1997;28:125–129.[PubMed][Google Scholar]
  • 178. Clark LC, Combs GF, Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr, Park HK, Sanders BB, Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957–1963.[PubMed]
  • 179. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Jr, Baker LH, Coltman CA., Jr Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301:39–51.
  • 180. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokersThe Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029–1035.[PubMed][Google Scholar]
  • 181. MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis P, Gratten H, Lambert J, Newland RC, Ngu M, Russell A, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst. 1995;87:1760–1766.[PubMed]
  • 182. Greenberg ER, Baron JA, Tosteson TD, Freeman DH, Jr, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med. 1994;331:141–147.[PubMed]
  • 183. Fung T, Hu FB, Fuchs C, Giovannucci E, Hunter DJ, Stampfer MJ, Colditz GA, Willett WCMajor dietary patterns and the risk of colorectal cancer in women. Arch Intern Med. 2003;163:309–314.[PubMed][Google Scholar]
  • 184. Dixon LB, Balder HF, Virtanen MJ, Rashidkhani B, Mannisto S, Krogh V, van Den Brandt PA, Hartman AM, Pietinen P, Tan F, Virtamo J, Wolk A, Goldbohm RADietary patterns associated with colon and rectal cancer: results from the Dietary Patterns and Cancer (DIETSCAN) Project. Am J Clin Nutr. 2004;80:1003–1011.[PubMed][Google Scholar]
  • 185. Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KNEating patterns and risk of colon cancer. Am J Epidemiol. 1998;148:4–16.[PubMed][Google Scholar]
  • 186. Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, Sandler RSDietary patterns, food groups, and rectal cancer risk in Whites and African-Americans. Cancer Epidemiol Biomarkers Prev. 2009;18:1552–1561.[Google Scholar]
  • 187. Giovannucci EAlcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies. J Nutr. 2004;134 2475S–2481S. [[PubMed][Google Scholar]
  • 188. Choi SY, Kahyo HEffect of cigarette smoking and alcohol consumption in the etiology of cancers of the digestive tract. Int J Cancer. 1991;49:381–386.[PubMed][Google Scholar]
  • 189. Chyou PH, Nomura AM, Stemmermann GNA prospective study of colon and rectal cancer among Hawaii Japanese men. Ann Epidemiol. 1996;6:276–282.[PubMed][Google Scholar]
  • 190. Ferraroni M, Negri E, La Vecchia C, D'Avanzo B, Franceschi SSocioeconomic indicators, tobacco and alcohol in the aetiology of digestive tract neoplasms. Int J Epidemiol. 1989;18:556–562.[PubMed][Google Scholar]
  • 191. Freudenheim JL, Graham S, Marshall JR, Haughey BP, Wilkinson GLifetime alcohol intake and risk of rectal cancer in western New York. Nutr Cancer. 1990;13:101–109.[PubMed][Google Scholar]
  • 192. Hermann S, Rohrmann S, Linseisen JLifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg. Cancer Causes Control. 2009[PubMed][Google Scholar]
  • 193. Hirayama TAssociation between alcohol consumption and cancer of the sigmoid colon: observations from a Japanese cohort study. Lancet. 1989;2:725–727.[PubMed][Google Scholar]
  • 194. Hu JF, Liu YY, Yu YK, Zhao TZ, Liu SD, Wang QQDiet and cancer of the colon and rectum: a case-control study in China. Int J Epidemiol. 1991;20:362–367.[PubMed][Google Scholar]
  • 195. Kabat GC, Howson CP, Wynder ELBeer consumption and rectal cancer. Int J Epidemiol. 1986;15:494–501.[PubMed][Google Scholar]
  • 196. Klatsky AL, Armstrong MA, Friedman GD, Hiatt RAThe relations of alcoholic beverage use to colon and rectal cancer. Am J Epidemiol. 1988;128:1007–1015.[PubMed][Google Scholar]
  • 197. Kune S, Kune GA, Watson LFCase-control study of alcoholic beverages as etiological factors: the Melbourne colorectal cancer study. Nutrition and Cancer. 1987;9:43–56.[PubMed][Google Scholar]
  • 198. Longnecker MPA case-control study of alcoholic beverage consumption in relation to risk of cancer of the right colon and rectum in men. Cancer Causes Control. 1990;1:5–14.[PubMed][Google Scholar]
  • 199. Meyer F, White EAlcohol and nutrients in relation to colon cancer in middle-aged adults. Am J Epidemiol. 1993;138:225–236.[PubMed][Google Scholar]
  • 200. Miller AB, Howe GR, Jain M, Craib KJ, Harrison LFood items and food groups as risk factors in a case-control study of diet and colo-rectal cancer. Int J Cancer. 1983;32:155–161.[PubMed][Google Scholar]
  • 201. Murata M, Tagawa M, Watanabe S, Kimura H, Takeshita T, Morimoto KGenotype difference of aldehyde dehydrogenase 2 gene in alcohol drinkers influences the incidence of Japanese colorectal cancer patients. Jpn J Cancer Res. 1999;90:711–719.[Google Scholar]
  • 202. Newcomb PA, Storer BE, Marcus PMCancer of the large bowel in women in relation to alcohol consumption: a case-control study in Wisconsin (United States) Cancer Causes Control. 1993;4:405–411.[PubMed][Google Scholar]
  • 203. Peters RK, Garabrant DH, Yu MC, Mack TMA case-control study of occupational and dietary factors in colorectal cancer in young men by subsite. Cancer Res. 1989;49:5459–5468.[PubMed][Google Scholar]
  • 204. Peters RK, Pike MC, Garabrant D, Mack TMDiet and colon cancer in Los Angeles County, California. Cancer Causes Control. 1992;3:457–473.[PubMed][Google Scholar]
  • 205. Pickle LW, Greene MH, Ziegler RG, Toledo A, Hoover R, Lynch HT, Fraumeni JF., Jr Colorectal cancer in rural Nebraska. Cancer Res. 1984;44:363–369.[PubMed]
  • 206. Pollack ES, Nomura AM, Heilbrun LK, Stemmermann GN, Green SBProspective study of alcohol consumption and cancer. N Engl J Med. 1984;310:617–621.[PubMed][Google Scholar]
  • 207. Tuyns AJ, Pequignot G, Gignoux M, Valla ACancers of the digestive tract, alcohol and tobacco. Int J Cancer. 1982;30:9–11.[PubMed][Google Scholar]
  • 208. Williams RR, Horm JWAssociation of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst. 1977;58:525–547.[PubMed][Google Scholar]
  • 209. Bidoli E, Franceschi S, Talamini R, Barra S, La Vecchia CFood consumption and cancer of the colon and rectum in north-eastern Italy. Int J Cancer. 1992;50:223–229.[PubMed][Google Scholar]
  • 210. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LAssocations of sedentary lifestyle, obesity, smoking, alcohol use and diabetes with the risk of colorectal cancer. Cancer Research. 1997;57:4787–4794.[PubMed][Google Scholar]
  • 211. Slattery ML, Schaffer D, Edwards SL, Ma KN, Potter JDAre dietary factors involved in DNA methylation associated with colon cancer? Nutr Cancer. 1997;28:52–62.[PubMed][Google Scholar]
  • 212. Slattery ML, West DW, Robison LM, French TK, Ford MH, Schuman KL, Sorenson AWTobacco, alcohol, coffee, and caffeine as risk factors for colon cancer in a low-risk population. Epidemiology. 1990;1:141–145.[PubMed][Google Scholar]
  • 213. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WCAlcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst. 1995;87:265–273.[PubMed][Google Scholar]
  • 214. Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, Speizer FE, Willett WCFolate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst. 1993;85:875–884.[PubMed][Google Scholar]
  • 215. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Holmberg L, Kim DH, Malila N, Miller AB, Pietinen P, Rohan TE, Sellers TA, Speizer FE, Willett WC, Wolk A, Hunter DJAlcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140:603–613.[PubMed][Google Scholar]
  • 216. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, Tjonneland A, Overvad K, Jensen MK, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Rohrmann S, Linseisen J, Boeing H, Bergmann M, Kontopoulou D, Trichopoulou A, Kassapa C, Masala G, Krogh V, Vineis P, Panico S, Tumino R, van Gils CH, Peeters P, Bueno-de-Mesquita HB, Ocke MC, Skeie G, Lund E, Agudo A, Ardanaz E, Lopez DC, Sanchez MJ, Quiros JR, Amiano P, Berglund G, Manjer J, Palmqvist R, Van Guelpen B, Allen N, Key T, Bingham S, Mazuir M, Boffetta P, Kaaks R, Riboli ELifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC) Int J Cancer. 2007;121:2065–2072.[PubMed][Google Scholar]
  • 217. Bagnardi V, Blangiardo M, La Vecchia C, Corrao GA meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85:1700–1705.[Google Scholar]
  • 218. Poynter JN, Haile RW, Siegmund KD, Campbell PT, Figueiredo JC, Limburg P, Young J, Le Marchand L, Potter JD, Cotterchio M, Casey G, Hopper JL, Jenkins MA, Thibodeau SN, Newcomb PA, Baron JAAssociations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 2009;18:2745–2750.[Google Scholar]
  • 219. Seitz HK, Simanowski UA, Garzon FT, Rideout JM, Peters TJ, Koch A, Berger MR, Einecke H, Maiwald MPossible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. Gastroenterology. 1990;98:406–413.[PubMed][Google Scholar]
  • 220. Choi SW, Stickel F, Baik HW, Kim YI, Seitz HK, Mason JBChronic alcohol consumption induces genomic but not p53-specific DNA hypomethylation in rat colon. J Nutr. 1999;129:1945–1950.[PubMed][Google Scholar]
  • 221. Kune GA, Vitetta LAlcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. Nutr Cancer. 1992;18:97–111.[PubMed][Google Scholar]
  • 222. Doll R, Peto RMortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976;2:1525–1536.[Google Scholar]
  • 223. Hammond EC, Horn D. Smoking and death rates: report on forty-four months of followup of 187,783 men. II. Death rates by cause. JAMA. 1958;166:1294–1308.[PubMed]
  • 224. Kahn HA. The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr. 1966;19:1–125.[PubMed]
  • 225. Rogot E, Murray JLSmoking and causes of death among US Veterans: 16 years of observation. Public Health Reports. 1980;95:213–222.[Google Scholar]
  • 226. Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, Speizer FE. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994;86:192–199.[PubMed]
  • 227. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Kearney J, Willett WC. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst. 1994;86:183–191.[PubMed]
  • 228. AnonymousTobacco smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1986;38:397.[PubMed][Google Scholar]
  • 229. Yamasaki E, Ames BNConcentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proceedings of the National Academy of Sciences of the United States of America. 1977;74:3555–3559.[Google Scholar]
  • 230. Giovannucci EAn updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention. 2001;10:725–731.[PubMed][Google Scholar]
  • 231. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels ABCigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134:388–395.[PubMed][Google Scholar]
  • 232. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve PSmoking and colorectal cancer: a meta-analysis. JAMA. 2008;300:2765–2778.[PubMed][Google Scholar]
  • 233. Liang PS, Chen TY, Giovannucci ECigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009;124:2406–2415.[PubMed][Google Scholar]
  • 234. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJCigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009;7:682–688. e1–5. [[PubMed][Google Scholar]
  • 235. Hannan LM, Jacobs EJ, Thun MJThe association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:3362–3367.[PubMed][Google Scholar]
  • 236. Limburg PJ, Vierkant RA, Cerhan JR, Yang P, Lazovich D, Potter JD, Sellers TACigarette smoking and colorectal cancer: long-term, subsite-specific risks in a cohort study of post-menopausal women. Clinical Gastroenterology and Hepatology. 2003;1:202–210.[PubMed][Google Scholar]
  • 237. Chao A, Thun MJ, Jacobs EJ, Henley SJ, Rodriguez C, Calle EECigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst. 2000;92:1888–1896.[PubMed][Google Scholar]
  • 238. Heineman EF, Zahm SH, McLaughlin JK, Vaught JBIncreased risk of colorectal cancer among smokers: results of a 26-year follow-up of US veterans and a review. Int J Cancer. 1994;59:728–738.[PubMed][Google Scholar]
  • 239. Newcomb PA, Storer BE, Marcus PMCigarette smoking in relation to risk of large bowel cancer in women. Cancer Res. 1995;55:4906–4909.[PubMed][Google Scholar]
  • 240. Abrams JA, Terry MB, Neugut AICigarette smoking and the colorectal adenoma-carcinoma sequence. Gastroenterology. 2008;134:617–619.[PubMed][Google Scholar]
  • 241. Lee IM, Paffenbarger RS, Jr, Hsieh CCPhysical activity and risk of developing colorectal cancer among college alumni. J Natl Cancer Inst. 1991;83:1324–1329.[PubMed][Google Scholar]
  • 242. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WCPhysical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327–334.[PubMed][Google Scholar]
  • 243. Martinez ME, Giovannucci E, Spiegelman D, Hunter DJ, Willett WC, Colditz GA. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst. 1997;89:948–955.[PubMed]
  • 244. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli EBody size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) J Natl Cancer Inst. 2006;98:920–931.[PubMed][Google Scholar]
  • 245. Giovannucci E, Colditz GA, Stampfer MJ, Willett WCPhysical activity, obesity, and risk of colorectal adenoma in women (United States) Cancer Causes Control. 1996;7:253–263.[PubMed][Google Scholar]
  • 246. Ning Y, Wang L, Giovannucci ELA quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2009[PubMed][Google Scholar]
  • 247. Larsson SC, Wolk AObesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556–565.[PubMed][Google Scholar]
  • 248. Giovannucci EInsulin and colon cancer. Cancer Causes Control. 1995;6:164–179.[PubMed][Google Scholar]
  • 249. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJA prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546–553.[PubMed][Google Scholar]
  • 250. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJAssociation of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:412–418.[PubMed][Google Scholar]
  • 251. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, Tjonneland A, Olsen A, Overvad K, Gronbaek H, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Boeing H, Pischon T, Trichopoulos D, Oikonomou E, Trichopoulou A, Panico S, Vineis P, Berrino F, Tumino R, Masala G, Peters PH, van Gils CH, Bueno-de-Mesquita HB, Ocke MC, Lund E, Mendez MA, Tormo MJ, Barricarte A, Martinez-Garcia C, Dorronsoro M, Quiros JR, Hallmans G, Palmqvist R, Berglund G, Manjer J, Key T, Allen NE, Bingham S, Khaw KT, Cust A, Kaaks RSerum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121:368–376.[PubMed][Google Scholar]
  • 252. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli ESerum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92:1592–1600.[PubMed][Google Scholar]
  • 253. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane SPlasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer. 2007;120:2007–2012.[PubMed][Google Scholar]
  • 254. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, Kaaks R, Stattin PComponents of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2007[PubMed][Google Scholar]
  • 255. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci EA prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005;14:850–855.[PubMed][Google Scholar]
  • 256. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CSLow plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–1694.[PubMed][Google Scholar]
  • 257. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y, Kawata SAssociation of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11:3642–3646.[PubMed][Google Scholar]
  • 258. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci EProspective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542–547.[PubMed][Google Scholar]
  • 259. Larsson SC, Giovannucci E, Wolk ADiabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care. 2005;28:1805–1807.[PubMed][Google Scholar]
  • 260. La Vecchia C, Negri E, Decarli A, Franceschi SDiabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 1997;6:1007–1010.[PubMed][Google Scholar]
  • 261. Limburg PJ, Anderson KE, Johnson TW, Jacobs DR, Jr, Lazovich D, Hong CP, Nicodemus KK, Folsom ARDiabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005;14:133–137.[PubMed][Google Scholar]
  • 262. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ, 3rd, Sellers TA, Cerhan JRClinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol. 2006;101:1872–1879.[PubMed][Google Scholar]
  • 263. Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, Tumino R, Mattiello A, Vineis P, Nieters A, Linseisen J, Pischon T, Boeing H, Hallmans G, Palmqvist R, Manjer J, Wirfalt E, Crowe FL, Khaw KT, Bingham S, Tjonneland A, Olsen A, Overvad K, Lund E, Skeie G, Clavel-Chapelon F, Boutron-Ruault MC, de Lauzon-Guillain B, Ardanaz E, Jakszyn P, Ramon Quiros J, Chirlaque MD, Sanchez MJ, Dorronsoro M, Trichopoulou A, Lagiou P, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Slimani N, Ferrari P, Byrnes GB, Riboli E, Kaaks RGlycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17:3108–3115.[PubMed][Google Scholar]
  • 264. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day NPreliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev. 2004;13:915–919.[PubMed][Google Scholar]
  • 265. Lin J, Ridker PM, Pradhan A, Lee IM, Manson JE, Cook NR, Buring JE, Zhang SMHemoglobin A1c concentrations and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005;14:3010–3012.[Google Scholar]
  • 266. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci EGlycosylated hemoglobin and risk of colorectal cancer and adenoma (United States) Cancer Causes Control. 1999;10:379–386.[PubMed][Google Scholar]
  • 267. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci EC-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006;15:750–755.[PubMed][Google Scholar]
  • 268. Shoelson SE, Herrero L, Naaz AObesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180.[PubMed][Google Scholar]
  • 269. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RSCirculating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68:323–328.[Google Scholar]
  • 270. Hotamisligil GSInflammation and metabolic disorders. Nature. 2006;444:860–867.[PubMed][Google Scholar]
  • 271. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen SAspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13:538–545.[PubMed][Google Scholar]
  • 272. Delage B, Rullier A, Capdepont M, Rullier E, Cassand PThe effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J. 2007;6:20.[Google Scholar]
  • 273. Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, Cole BF, Haile RW, Sandler RSAspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States) Cancer Causes Control. 2006;17:1299–1304.[PubMed][Google Scholar]
  • 274. Colbert LH, Hartman TJ, Malila N, Limburg PJ, Pietinen P, Virtamo J, Taylor PR, Albanes DPhysical activity in relation to cancer of the colon and rectum in a cohort of male smokers. Cancer Epidemiol Biomarkers Prev. 2001;10:265–268.[PubMed][Google Scholar]
  • 275. Colditz G, Cannuscio C, Frazier APhysical activity and reduced risk of colon cancer: implications for prevention. Cancer Causes Control. 1997;8:649–667.[PubMed][Google Scholar]
  • 276. Kono S, Shinchi K, Ikeda N, Yanai F, Imanishi KPhysical activity, dietary habits and adenomatous polyps of the sigmoid colon: a study of self-defense officials in Japan. Journal of Clinical Epidemiology. 1991;44:1255–1261.[PubMed][Google Scholar]
  • 277. Neugut AI, Terry MB, Hocking G, Mosca L, Garbowski GC, Forde KA, Treat MR, Waye JLeisure and occupational physical activity and risk of colorectal adenomatous polyps. International Journal of Cancer. 1996;68:744–748.[PubMed][Google Scholar]
  • 278. Thun MJ, Calle EE, Namboodiri MM, Flanders WD, Coates RJ, Byers T, Boffetta P, Garfinkel L, Heath CW., Jr Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992;84:1491–1500.[PubMed]
  • 279. Martinez ME, Giovannucci E, Spiegelman D, Stampfer MJ, Hunter DJ, Speizer FE, Willett WC, Colditz GAPhysical activity, body size, and colorectal cancer in women. Am J Epidemiol. 1996;143:S73.[PubMed][Google Scholar]
  • 280. Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma K-N, Berry TDEnergy balance and colon cancer--beyond physical activity. Cancer Res. 1997;57:75–80.[PubMed][Google Scholar]
  • 281. Wolin KY, Yan Y, Colditz GA, Lee IMPhysical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611–616.[Google Scholar]
  • 282. Dowse GK, Zimmet PZ, Gareeboo H, George K, Alberti MM, Tuomilehto J, Finch CF, Chitson P, Tulsidas HAbdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care. 1991;14:271–282.[PubMed][Google Scholar]
  • 283. Regensteiner JG, Mayer EJ, Shetterly SM, Eckel RH, Haskell WL, Marshall JA, Baxter J, Hamman RF. Relationship between habitual physical activity and insulin levels among nondiabetic men and women. San Luis Valley Diabetes Study. Diabetes Care. 1991;14:1066–1074.[PubMed]
  • 284. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, Goebell H. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion. 2000;61:129–134.[PubMed]
  • 285. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro SNSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control. 2000;11:249–255.[PubMed][Google Scholar]
  • 286. Friedman GD, Coates AO, Potter JD, Slattery MLDrugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998;7:99–106.[PubMed][Google Scholar]
  • 287. Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, McLaughlin JK, Blot WJ, Olsen JHAspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009;20:731–740.[PubMed][Google Scholar]
  • 288. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JHA population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88:684–688.[Google Scholar]
  • 289. Garcia Rodriguez LA, Huerta-Alvarez CReduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376–381.[PubMed][Google Scholar]
  • 290. Garcia-Rodriguez LA, Huerta-Alvarez CReduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:471–472.[PubMed][Google Scholar]
  • 291. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JANonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267–276.[Google Scholar]
  • 292. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EEA large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99:608–615.[PubMed][Google Scholar]
  • 293. Juarranz M, Calle-Puron ME, Gonzalez-Navarro A, Regidor-Poyatos E, Soriano T, Martinez-Hernandez D, Rojas VD, Guinee VFPhysical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur J Cancer Prev. 2002;11:465–472.[PubMed][Google Scholar]
  • 294. Kahn HS, Tatham LM, Thun MJ, Heath CW., Jr Risk factors for self-reported colon polyps. J Gen Intern Med. 1998;13:303–310.
  • 295. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli AAspirin and colorectal cancer. Br J Cancer. 1997;76:675–677.[Google Scholar]
  • 296. Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JDRisk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002;11:1012–1018.[PubMed][Google Scholar]
  • 297. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JTAspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114:441–447.[PubMed][Google Scholar]
  • 298. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JARisk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88:1687–1692.[Google Scholar]
  • 299. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, Burt R, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin ANon-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States) Cancer Causes Control. 2003;14:403–411.[PubMed][Google Scholar]
  • 300. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FMLong-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002;122:641–645.[PubMed][Google Scholar]
  • 301. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJTreatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316.[PubMed][Google Scholar]
  • 302. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber NRofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci. 2003;48:1998–2002.[PubMed][Google Scholar]
  • 303. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali PSulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–639.[PubMed][Google Scholar]
  • 304. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JMEffects of long-term sulindac therapy on colonic polyposis. Ann Intern Med. 1991;115:952–954.[PubMed][Google Scholar]
  • 305. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin BThe effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England Journal of Medicine. 2000;342:1946–1952.[PubMed][Google Scholar]
  • 306. Waddell WR, Ganser GF, Cerise EJ, Loughry RWSulindac for polyposis of the colon. Am J Surg. 1989;157:175–179.[PubMed][Google Scholar]
  • 307. Waddell WR, Loughry RWSulindac for polyposis of the colon. J Surg Oncol. 1983;24:83–87.[PubMed][Google Scholar]
  • 308. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RUA randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899.[PubMed][Google Scholar]
  • 309. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade SDaily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328–336.[PubMed][Google Scholar]
  • 310. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky RA randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890.[PubMed][Google Scholar]
  • 311. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JAAspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–266.[Google Scholar]
  • 312. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JELow-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Jama. 2005;294:47–55.[PubMed][Google Scholar]
  • 313. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CHLow-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–1224.[PubMed][Google Scholar]
  • 314. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CSAspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21–28.[Google Scholar]
  • 315. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CSLong-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Jama. 2005;294:914–923.[Google Scholar]
  • 316. Flossmann E, Rothwell PMEffect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–1613.[PubMed][Google Scholar]
  • 317. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GC, Hunter DJ, Willett WC, Fuchs CSA prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med. 2004;140:157–166.[PubMed][Google Scholar]
  • 318. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CSGenetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst. 2005;97:457–460.[PubMed][Google Scholar]
  • 319. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JDCYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001;61:3566–3569.[PubMed][Google Scholar]
  • 320. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin BCelecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.[PubMed][Google Scholar]
  • 321. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DGA randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–1682.[PubMed][Google Scholar]
  • 322. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ETCelecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884.[PubMed][Google Scholar]
  • 323. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DLCardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–1764.[PubMed][Google Scholar]
  • 324. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JACardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med. 2005;352:1092–1102.[PubMed][Google Scholar]
  • 325. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli MCardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N Engl J Med. 2005;352:1071–1080.[PubMed][Google Scholar]
  • 326. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes JEffect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028–1035.[PubMed][Google Scholar]
  • 327. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk ECardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104–2113.[Google Scholar]
  • 328. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ETFive-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2009;2:310–321.[Google Scholar]
  • 329. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong BC, Lam SKPrevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. Jama. 2007;298:1412–1419.[PubMed][Google Scholar]
  • 330. Boyapati SM, Bostick RM, McGlynn KA, Fina MF, Roufail WM, Geisinger KR, Wargovich M, Coker A, Hebert JRCalcium, vitamin D, and risk for colorectal adenoma: dependency on vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug use? Cancer Epidemiol Biomarkers Prev. 2003;12:631–637.[PubMed][Google Scholar]
  • 331. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim LColorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81:62–68.[Google Scholar]
  • 332. Hauret KG, Bostick RM, Matthews CE, Hussey JR, Fina MF, Geisinger KR, Roufail WMPhysical activity and reduced risk of incident sporadic colorectal adenomas: observational support for mechanisms involving energy balance and inflammation modulation. Am J Epidemiol. 2004;159:983–992.[PubMed][Google Scholar]
  • 333. Kim S, Martin C, Galanko J, Woosley JT, Schroeder JC, Keku TO, Satia JA, Halabi S, Sandler RSUse of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol. 2008;168:1292–1300.[Google Scholar]
  • 334. Kune GA, Kune S, Watson LFColorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–4404.[PubMed][Google Scholar]
  • 335. Lieberman DA, Prindiville S, Weiss DG, Willett WRisk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. Jama. 2003;290:2959–2967.[PubMed][Google Scholar]
  • 336. Lipworth L, Friis S, Blot WJ, McLaughlin JK, Mellemkjaer L, Johnsen SP, Norgaard B, Olsen JHA population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther. 2004;11:156–163.[PubMed][Google Scholar]
  • 337. Logan RF, Little J, Hawtin PG, Hardcastle JDEffect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 1993;307:285–289.[Google Scholar]
  • 338. Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, Schliebe B, Lund PK, Sandler RSNonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123:1770–1777.[PubMed][Google Scholar]
  • 339. Martinez ME, McPherson RS, Levin B, Annegers JFAspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev. 1995;4:703–707.[PubMed][Google Scholar]
  • 340. Muscat JE, Stellman SD, Wynder ELNonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994;74:1847–1854.[PubMed][Google Scholar]
  • 341. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CMLong-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci. 1996;41:1319–1326.[PubMed][Google Scholar]
  • 342. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PLNonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996;5:955–960.[PubMed][Google Scholar]
  • 343. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RSUse of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol. 2005;162:548–558.[PubMed][Google Scholar]
  • 344. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, de Cotret AR, Player J, Sandler RSCOX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States) Cancer Causes Control. 2006;17:257–266.[PubMed][Google Scholar]
  • 345. Shadman M, Newcomb PA, Hampton JM, Wernli KJ, Trentham-Dietz ANon-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol. 2009;15:2336–2339.[Google Scholar]
  • 346. Smalley W, Ray WA, Daugherty J, Griffin MRUse of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159:161–166.[PubMed][Google Scholar]
  • 347. Meyskens FL, Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg WEffect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 1998;90:1212–1218.[PubMed][Google Scholar]
  • 348. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL., Jr Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila Pa) 2008;1:514–521.
  • 349. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FLRisk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila Pa) 2009;2:209–212.[Google Scholar]
  • 350. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MMSuppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell. 1996;87:803–809.[PubMed][Google Scholar]
  • 351. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RNHost cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589–1594.[Google Scholar]
  • 352. Dubois RNReview article: cyclooxygenase--a target for colon cancer prevention. Aliment Pharmacol Ther. 2000;14 Suppl 1:64–67.[PubMed][Google Scholar]
  • 353. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RNUp-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–1188.[PubMed][Google Scholar]
  • 354. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, Moretto J, Mendes F, Smith AP, Bennington JL, Moore D, Lee NMAlteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 2004;64:3694–3700.[PubMed][Google Scholar]
  • 355. Chan AT, Ogino S, Fuchs CSAspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–2142.[PubMed][Google Scholar]
  • 356. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JACyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2009;18:2726–2733.[Google Scholar]
  • 357. Kopp E, Ghosh SInhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–959.[PubMed][Google Scholar]
  • 358. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek JSodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci U S A. 1997;94:2869–2873.[Google Scholar]
  • 359. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EWPronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A. 2003;100:7859–7864.[Google Scholar]
  • 360. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.SPreventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–364.[PubMed][Google Scholar]
  • 361. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:376–389.[PubMed]
  • 362. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JRAssociation of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99:881–889.[PubMed][Google Scholar]
  • 363. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CSNonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–1587.[PubMed][Google Scholar]
  • 364. Limburg PJ, Cerhan JRAspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell? Gastroenterology. 2007;133:717–718.[PubMed][Google Scholar]
  • 365. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:365–375.[PubMed]
  • 366. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun MAspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–507.[PubMed][Google Scholar]
  • 367. Chan AT, Ogino S, Fuchs CSAspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649–658.[Google Scholar]
  • 368. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver HNonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer. 2009[Google Scholar]
  • 369. Dornschneider G, Izbicki JR, Wilker DK, Schweiberer LThe effects of sex steroids on colon carcinogenesis. Anticancer Drugs. 1990;1:15–21.[PubMed][Google Scholar]
  • 370. McMichael AJ, Potter JDHost factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst. 1985;75:185–191.[PubMed][Google Scholar]
  • 371. Lampe JW, Fredstrom SB, Slavin JL, Potter JDSex differences in colonic function: a randomised trial. Gut. 1993;34:531–536.[Google Scholar]
  • 372. Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C, Peris C, Fiorucci GC, Sismondi PDifferential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol. 1993;7:251–258.[PubMed][Google Scholar]
  • 373. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SBMethylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536–540.[PubMed][Google Scholar]
  • 374. Risch HA, Howe GRMenopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev. 1995;4:21–28.[PubMed][Google Scholar]
  • 375. Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF., Jr A prospective study of menopausal hormones and risk of colorectal cancer (United States) Cancer Causes Control. 1997;8:130–138.[PubMed]
  • 376. Weiss NS, Daling JR, Chow WHIncidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst. 1981;67:57–60.[PubMed][Google Scholar]
  • 377. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW., Jr Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517–523.[PubMed]
  • 378. Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino LMenopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol. 2008;19:150–155.[PubMed][Google Scholar]
  • 379. Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F, Franceschi SHormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:329–333.[PubMed][Google Scholar]
  • 380. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JDHormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85:1128–1132.[Google Scholar]
  • 381. Furner SE, Davis FG, Nelson RL, Haenszel WA case-control study of large bowel cancer and hormone exposure in women. Cancer Res. 1989;49:4936–4940.[PubMed][Google Scholar]
  • 382. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979;133:537–547.[PubMed]
  • 383. Jacobs EJ, White E, Weiss NSExogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA) Cancer Causes Control. 1994;5:359–366.[PubMed][Google Scholar]
  • 384. Johnson JR, Lacey JV, Jr, Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood AMenopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:196–203.[Google Scholar]
  • 385. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards SHormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control. 1997;8:146–158.[PubMed][Google Scholar]
  • 386. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EMEstrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74–79.[PubMed][Google Scholar]
  • 387. Paganini-Hill AEstrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum. 1999;42:1300–1305.[PubMed][Google Scholar]
  • 388. Persson I, Yuen J, Bergkvist L, Schairer CCancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67:327–332.[PubMed][Google Scholar]
  • 389. Peters RK, Pike MC, Chang WW, Mack TMReproductive factors and colon cancers. Br J Cancer. 1990;61:741–748.[Google Scholar]
  • 390. Potter JD, McMichael AJLarge bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst. 1983;71:703–709.[PubMed][Google Scholar]
  • 391. Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg LA case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:443–447.[PubMed][Google Scholar]
  • 392. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SBUse of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009;27:4542–4547.[Google Scholar]
  • 393. Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, Schaffer D, Samowitz WSEstrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61:126–1230.[PubMed][Google Scholar]
  • 394. Jacobson JS, Neugut AI, Garbowski GC, Ahsan H, Waye JD, Treat MR, Forde KAReproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States) Cancer Causes Control. 1995;6:513–518.[PubMed][Google Scholar]
  • 395. Peipins LA, Newman B, Sandler RSReproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1997;6:671–675.[PubMed][Google Scholar]
  • 396. Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J, Grambsch P, Louis TAHormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev. 1996;5:779–784.[PubMed][Google Scholar]
  • 397. Wolf LA, Terry PD, Potter JD, Bostick RMDo factors related to endogenous and exogenous estrogens modify the relationship between obesity and risk of colorectal adenomas in women? Cancer Epidemiol Biomarkers Prev. 2007;16:676–683.[PubMed][Google Scholar]
  • 398. Woodson K, Lanza E, Tangrea JA, Albert PS, Slattery M, Pinsky J, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin AHormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst. 2001;93:1799–1805.[PubMed][Google Scholar]
  • 399. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJPostmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705–712.[PubMed][Google Scholar]
  • 400. Grodstein F, Newcomb PA, Stampfer MJPostmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–582.[PubMed][Google Scholar]
  • 401. Hebert-Croteau NA meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7:653–659.[PubMed][Google Scholar]
  • 402. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene JRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.[PubMed][Google Scholar]
  • 403. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski RTConjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17:2609–2618.[Google Scholar]
  • 404. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JDEstrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67:7534–7539.[PubMed][Google Scholar]
  • 405. Tannen RL, Weiner MG, Xie D, Barnhart KEstrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod. 2007;22:1769–1777.[PubMed][Google Scholar]
  • 406. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, Gapstur SMColorectal Cancer Incidence and Postmenopausal Hormone Use by Type, Recency, and Duration in Cancer Prevention Study II. Cancer Epidemiol Biomarkers Prev. 2009[PubMed][Google Scholar]
  • 407. Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, Stefanick ML, Chlebowski RTColorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev. 2009;18:1531–1537.[Google Scholar]
  • 408. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci EProportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11:579–588.[PubMed][Google Scholar]
  • 409. Parkin DM, Olsen AH, Sasieni PThe potential for prevention of colorectal cancer in the UK. Eur J Cancer Prev. 2009;18:179–190.[PubMed][Google Scholar]
  • 410. Wei EK, Colditz GA, Giovannucci EL, Fuchs CS, Rosner BACumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study. American Journal of Epidemiology. 2009;170:863–872.[Google Scholar]
  • 411. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski ASProstaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289–293.[PubMed][Google Scholar]
  • 412. He TC, Chan TA, Vogelstein B, Kinzler KWPPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335–345.[Google Scholar]
  • 413. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SAPeroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406–3410.[PubMed][Google Scholar]
  • 414. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CSThe cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275:11397–11403.[PubMed][Google Scholar]
  • 415. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103:12098–12102.[Google Scholar]
  • 416. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM, Markowitz SD15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A. 2009;106:9409–9413.[Google Scholar]
  • 417. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004;101:17468–17473.[Google Scholar]
  • 418. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, Wen W, Rothman N, Li HL, Morrow JD, Zheng WProspective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol. 2006;24:5010–5016.[PubMed][Google Scholar]
  • 419. Chen J, Giovannucci EL, Hunter DJ. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J Nutr. 1999;129 560S-564S. [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.